

## 1. Company details

Name of entity:	Virtus Health Limited
ABN:	80 129 643 492
Reporting period:	For the year ended 30 June 2015
Previous period:	For the year ended 30 June 2014

## 2. Results for announcement to the market

			\$'000
Revenues from ordinary activities	up	16.1% to	233,696
Earnings Before Interest, Tax, Depreciation and Amortisation (EBITDA)	up	3.3% to	61,355
Earnings Before Interest and Tax (EBIT)	up	0.3% to	51,361
Profit from ordinary activities after tax attributable to the owners of Virtus Health Limited	down	4.7% to	29,434
Profit for the year attributable to the owners of Virtus Health Limited	down	4.7% to	29,434

### Dividends

	Amount per security Cents	Franked amount per security Cents
Interim ordinary dividend for the year ended 30 June 2015 of 13.0 cents per fully paid share paid in April 2015	13.000	13.000
Final ordinary dividend for the year ended 30 June 2014 of 14.0 cents per fully paid ordinary share paid in October 2014	14.000	14.000

### Comments

The profit for the consolidated entity after providing for income tax and non-controlling interest amounted to \$29,434,000 (30 June 2014: \$30,885,000).

	Consolidated 2015 \$'000	2014 \$'000
Segment EBITDA	70,977	67,881
Share-based payment expense	(945)	(456)
Net gain on acquisition of associate	300	-
Other non-trading expenses	(8,977)	(8,021)
EBITDA (reported)	61,355	59,404
Depreciation and amortisation expense	(9,994)	(8,192)
EBIT	51,361	51,212
Interest revenue	220	349
Interest expense	(7,235)	(7,211)
Interest on other financial liability - non-cash interest	(960)	(45)
Amortisation of bank facility fee	(911)	(463)
Profit before income tax from continuing activities	42,475	43,842

Key features of the results are:

- Revenue increased by 16.1% to \$233.7m;
- Group EBITDA increased by 3.3% to \$61.4m;
- Segment EBITDA increased by 4.6% to \$71.0m;
- Australian segment EBITDA increased by 1.9% to \$68.6m;
- International segment EBITDA was \$2.4m including Singapore operation start-up losses and international business development expenses of \$1.9m;
- Net profit after tax ("NPAT") decreased by 1.7% to \$30.4m; and
- Adjusted NPAT after adding back non-recurring expenses and non-cash acquisition related interest increased by 5.1% to \$33.6m.

Segment EBITDA in Australia was adversely affected by a change in clinical practice at Melbourne IVF. The clinical and scientific team implemented a combined 'blastocyst' (five day embryo) and two day embryo transfer protocol with the specific protocol applied being determined by the scientific and clinical team. The change in practice resulted in a slight reduction in the number of fresh cycles and a more significant reduction in frozen cycles undertaken and this translated into a revenue loss of approximately \$3m compared to the prior year. In the period since the change was effected Melbourne IVF has recorded improvements in their implantation rates for fresh and frozen embryos.

Adjusted NPAT is calculated after adding back non-recurring expenses and non-cash acquisition related interest totalling \$3,174,000. Details of this adjustment are set out below:

- Singapore set-up costs of \$911,000;
- A gain of \$300,000 on the acquisition of Sunshine Coast IVF;
- Acquisition transaction costs of \$1,146,000;
- Non-cash interest of \$960,000 related to non-current liability to acquire non-controlling interests;
- Amortisation of bank fees of \$653,000 relating to the retired borrowing facility; and
- Tax effect credit of \$196,000 related to the above items.

#### *Operating overview*

##### *Australia*

There was an overall market volume increase in New South Wales, Queensland, Tasmania and Victoria of 1.4% for Assisted Reproductive Services ("ARS") and the eastern state market outlook remains subdued. (Note: market volume reflects fresh and cancelled cycles).

Underlying cycle volume in Virtus clinics declined by 1.6% with growth in New South Wales offset by a decline in Victoria and continued weakness in the Queensland market. Virtus continues to experience growth in its "The Fertility Centre" branded clinics with all states meeting growth objectives however this growth has been offset by weakness in full service cycles. Growth has been impacted by the following factors:

- Although market growth in NSW has improved in the twelve months to 30 June by 4.5% compared to prior year comparatives (Source: Medicare Statistics for item numbers 13200,13201,13202), as previously disclosed Virtus has not achieved comparable cycle growth. Virtus believes the market growth is attributable to the increased activity of the bulk bill provider in NSW;
- Virtus has lost a small amount of market share in Victoria and Queensland in the financial year. In addition the state markets have remained weak with Victorian market contracting 1.3% and Queensland market unchanged against prior year comparatives;

IVFA Australia opened a new The Fertility Centre ("TFC") ARS facility in Wollongong, New South Wales. Virtus now has six TFCs in Australia.

Specialist diagnostic revenue increased by 14.6% in FY2015, with greater utilization of cytogenetic and non-invasive pre-natal testing activities. Diagnostic test revenue growth continues to be a focus for the business and Virtus has invested in new gene sequencing equipment to further develop our capability and patient services in our PGD and genetic activities in Melbourne and Brisbane. We recently announced the arrival of the first babies born using our new Karyomapping diagnostic technology.

In our day hospitals Virtus achieved revenue growth of 4.3% with non-IVF revenue growth of 8.7% offsetting the weakness in IVF procedure revenue. City West Specialist Day Hospital in Sydney performed particularly well, and several locations improved their non-IVF procedure activity which now accounts for 56% of day hospital revenue.

#### *International*

Virtus completed the development and commissioning of a new Virtus branded clinic in Singapore. Operating EBITDA loss for the activity in Singapore was \$1,905,000 in the financial year. Virtus has contracted three fertility specialists in Singapore and IVF cycles commenced during late February 2015; four non-contracted fertility specialists are also using the facility for some of their ARS activities.

Sims Clinic, acquired in May 2014, enjoyed a strong year with volumes increasing by 11% compared to FY2014; EBITDA margin improved to 21% of revenue after absorbing start-up costs for our new full service Cork clinic; volumes have improved steadily since opening in January 2015.

#### *Capital Expenditure*

Total expenditure on tangible and intangible assets was \$12.6m in FY2015 (FY2014; \$8.0m) including approximately \$3.4m in our new facility in Singapore. We also invested in new fertility clinics in Wollongong, NSW and Cork, Ireland.

#### *Acquisitions*

Virtus completed three acquisitions during the year:

- IVF Sunshine Coast – since acquiring the remaining 80% of this full service clinic at the end of October 2014, in conjunction with the three fertility specialists and the Scientific Director Virtus has established two new clinics:
  - IVF Sunshine Coast, a full service clinic based in Buderim; and
  - a new TFC, based at Kawana Private Hospital
- Tas IVF – Virtus acquired 70% of Tasmania's leading IVF clinic based in Hobart on 5 December 2014; and
- Human Assisted Reproductions Limited, ("Rotunda IVF") - our 70% owned subsidiary, Sims Clinic acquired an Irish fertility centre, the HARI clinic from the Rotunda Hospital in Dublin for €6 million on 31 December 2014.

#### *Outlook*

The long term trend of women over 30 delaying the birth of children is a key factor in each of our geographic markets and the demand for ARS is expected to grow. Although market growth rate has moderated in Australia, Virtus believes that demand for ARS will be supported by a range of social and demographic drivers and also, continued improvements in success rates and the application of specialist diagnostic services.

#### *Debt and Interest Expense*

Virtus negotiated a new Syndicate Facility Agreement with the existing group of facility providers and this was completed in October 2014. The total facility available was increased by \$60m to \$210m and the consolidated entity comfortably met the financial covenants as set out in the agreement.

At 30 June 2015, total facilities drawn were \$153m in cash and \$3,430,000 in guarantees. Cash balances at the end of June 2015 were \$18,371,000.

#### *Other financial liabilities (\$24.7m)*

The non-controlling interests of Sims Clinic Limited and Tas IVF Pty Limited hold put options established at the time of acquisition. Consequently in accordance with accounting standards the group is required to recognise a liability for the estimated consideration to acquire the non-controlling interests. This liability has been discounted at the date of acquisition and the corresponding entry is included in the business combinations reserve. The unwinding of the inherent discounting within the liability has resulted in a non-cash interest expense in FY2015 of \$960,000 (FY2014 \$45,000).

#### *Amortisation of Borrowing Costs*

Amortisation of borrowing cost expense for FY2015 was \$911,000, including a write off of \$653,000 in respect of the now retired Syndicate Facility Agreement originally established at the IPO in June 2013.

#### *Taxation*

The effective tax rate on operating earnings for FY2015 was 28.3% (FY2014; 29.4%) as a consequence of the true-up of the prior year R&D tax concession and also the lower tax rate applied to the Virtus Ireland activities.

#### *Earnings per share*

Basic earnings per share decreased by 5.0% to 36.86 cents per share (FY2014: 38.80 cents per share). Diluted earnings per share decreased by 5.0% to 36.54 cents per share (FY2014: 38.48 cents per share).

#### Dividend

A final dividend of 14.00 cents per share fully franked (October 2014:14.00 cents per share) will be paid on 16 October to shareholders on the register at 2 October 2015.

### 3. Net tangible assets

	Reporting period Cents	Previous period Cents
Net tangible assets per ordinary security	(180.70)	(146.07)

### 4. Control gained over entities

Name of entities (or group of entities)	Human Assisted Reproduction Ireland (HARI) Limited, TAS IVF Pty Ltd and IVF Sunshine Coast Pty Limited
Date control gained	31 December 2014, 5 December 2014 and 31 October 2014 respectively
	\$'000
Contribution of such entities to the reporting entity's profit/(loss) from ordinary activities before income tax during the period (where material)	1,762
Profit/(loss) from ordinary activities before income tax of the controlled entity (or group of entities) for the whole of the previous period (where material)	3,448

### 5. Loss of control over entities

Name of entities (or group of entities)	Not Applicable
Date control lost	
	\$'000
Contribution of such entities to the reporting entity's profit/(loss) from ordinary activities before income tax during the period (where material)	-
Profit/(loss) from ordinary activities before income tax of the controlled entity (or group of entities) whilst controlled during the whole of the previous period (where material)	-

### 6. Dividends

#### Current period

	Amount per security Cents	Franked amount per security Cents
Interim ordinary dividend for the year ended 30 June 2015 of 13.0 cents per fully paid share paid in April 2015	13.000	13.000
Final ordinary dividend for the year ended 30 June 2014 of 14.0 cents per fully paid ordinary share paid in October 2014	14.000	14.000

Previous period

	Amount per security Cents	Franked amount per security Cents
Interim ordinary dividend for the year ended 30 June 2014 of 12.0 cents per fully paid share paid in April 2014	12.000	12.000

## 7. Dividend reinvestment plans

Not applicable.

## 8. Details of associates and joint venture entities

Name of associate / joint venture	Reporting entity's percentage holding		Contribution to profit/(loss) (where material)	
	Reporting period %	Previous period %	Reporting period \$'000	Previous period \$'000
Obstetrics and Gynaecological Imaging Australia Pty Limited and City West Specialist Hospital Pty Limited	50.00%	50.00%	563	189
<i>Group's aggregate share of associates and joint venture entities' profit/(loss) (where material)</i>				
Profit/(loss) from ordinary activities before income tax			563	189
Income tax on operating activities			-	-

## 9. Foreign entities

*Details of origin of accounting standards used in compiling the report:*

IFRS has been applied to the foreign entities of Virtus Health.

## 10. Audit qualification or review

*Details of audit/review dispute or qualification (if any):*

The financial statements have been audited and an unqualified opinion has been issued.

## 11. Attachments

*Details of attachments (if any):*

The Annual Report of Virtus Health Limited for the year ended 30 June 2015 is attached.

**12. Signed**

Signed

A handwritten signature in blue ink, appearing to read "Glenn Powers", written over a horizontal line.

Glenn Powers  
Chief Financial Officer and Company Secretary  
Sydney

Date: 25 August 2015

# **Virtus Health Limited**

**ABN 80 129 643 492**

## **Annual Report - 30 June 2015**

Directors	Peter Macourt - Chairman Susan Channon Dennis O'Neill Lyndon Hale Peter Turner Sonia Petering
Company secretary	Glenn Powers
Notice of annual general meeting	The details of the annual general meeting of Virtus Health Limited are: Wednesday 28 October 2015 at the Hilton Sydney at 2pm 488 George St Sydney NSW 2000
Registered office	Level 3 176 Pacific Highway Greenwich NSW 2065 Phone: (02) 9425 1722 Fax: (02) 9425 1633
Principal place of business	Level 3 176 Pacific Highway Greenwich NSW 2065
Share register	Link Market Services Limited Level 12 680 George Street Sydney NSW 2000 Phone: 1300 554 474
Auditor	PricewaterhouseCoopers Darling Park Tower 2 201 Sussex Street Sydney NSW 1171
Solicitors	Minter Ellison Aurora Place 88 Phillip Street Sydney NSW 2000
Bankers	Australia and New Zealand Banking Group Limited 242 Pitt Street Sydney NSW 2000 Westpac Banking Corporation Level 3, 275 Kent Street Sydney NSW 2000 Commonwealth Bank of Australia Ground floor, Tower 1 201 Sussex Street Sydney NSW 2000 Siemens Financial Services Inc 170 Wood Avenue, South Iselin New Jersey 08830, New Jersey 08830, United States of America National Australia Bank Level 19, NAB House 255 George Street Sydney NSW 2000
Stock exchange listing	Virtus Health Limited shares are listed on the Australian Securities Exchange (ASX code: VRT)
Website	<a href="http://www.virtushealth.com.au">www.virtushealth.com.au</a>
Corporate Governance Statement	The Corporate Governance Statement was approved by the Board of Directors on 21 August 2015 and can be found at <a href="http://virtushealth.com.au/about-us/corporate-governance">http://virtushealth.com.au/about-us/corporate-governance</a>



The directors present their report, together with the financial statements, on the consolidated entity (referred to hereafter as the 'consolidated entity') consisting of Virtus Health Limited (referred to hereafter as the 'company' or 'parent entity') and the entities it controlled at the end of, or during, the year ended 30 June 2015.

### **Directors**

The following persons were directors of Virtus Health Limited during the whole of the financial year and up to the date of this report, unless otherwise stated:

Peter Macourt - Chairman  
 Susan Channon  
 Dennis O'Neill  
 Lyndon Hale  
 Peter Turner  
 Sonia Petering (appointed on 1 September 2014)  
 Marcus Darville (resigned on 7 October 2014)

### **Principal activities**

During the financial year the principal continuing activities of the consolidated entity were the provision of healthcare services which include fertility services, medical day procedure services and medical diagnostic services.

### **Dividends**

Dividends paid during the financial year were as follows:

	<b>Consolidated</b>	
	<b>2015</b>	<b>2014</b>
	<b>\$'000</b>	<b>\$'000</b>
Interim ordinary dividend for the year ended 30 June 2015 of 13.0 cents (2014: 12.0 cents) per fully paid share paid in April 2015	10,385	9,446
Final ordinary dividend for the year ended 30 June 2014 of 14.0 cents per fully paid ordinary share paid in October 2014	10,915	-
	<u>21,300</u>	<u>9,446</u>

A final dividend of 14.00 cents per share, fully franked, will be paid on 16 October 2015 to the shareholders on the register at 2 October 2015.

### **Review of operations**

The profit for the consolidated entity after providing for income tax and non-controlling interest amounted to \$29,434,000 (30 June 2014: \$30,885,000).

A reconciliation of Segment EBITDA to profit before tax for the year is as follows:

	<b>Consolidated</b>	
	<b>2015</b>	<b>2014</b>
	<b>\$'000</b>	<b>\$'000</b>
Segment EBITDA	70,977	67,881
Share-based payment expense	(945)	(456)
Net gain on acquisition of associate	300	-
Other non-trading expenses	(8,977)	(8,021)
EBITDA (reported)	61,355	59,404
Depreciation and amortisation expense	(9,994)	(8,192)
EBIT	51,361	51,212
Interest revenue	220	349
Interest expense	(7,235)	(7,211)
Interest on other financial liability - non-cash interest	(960)	(45)
Amortisation of bank facility fee	(911)	(463)
Profit before income tax from continuing activities	<u>42,475</u>	<u>43,842</u>

The consolidated entity continued to engage in its principal activities, the results of which are disclosed in the attached financial statements.

For further information on review of operations, please refer to the Chief Executive's operating and financial review which precedes this Directors' report.

#### **Significant changes in the state of affairs**

In September 2014 Virtus Health renegotiated and extended its bank facilities to September 2019 and added a further \$60 million debt capacity to support its growth and acquisition strategies.

Virtus Health acquired 80% of the issued share capital and units of IVF Sunshine Coast Pty Ltd on 31 October 2014; 70% of the issued share capital and units of Tas IVF Pty Ltd on 5 December 2014; and formed a new company, Human Assisted Reproduction Ireland on 31 December 2014 to acquire the IVF business and assets from The Governors and Guardians of the Hospital For The Relief Of Poor Lying In Women, Dublin (commonly known as the Rotunda Hospital). For more information please refer to note 40.

Virtus Health also established a clinic in Singapore, Virtus Fertility Centre Singapore Limited; the clinic commenced operations in December 2014.

There were no other significant changes in the state of affairs of the consolidated entity during the financial year.

#### **Matters subsequent to the end of the financial year**

No matter or circumstance has arisen since 30 June 2015 that has significantly affected, or may significantly affect the consolidated entity's operations, the results of those operations, or the consolidated entity's state of affairs in future financial years.

#### **Likely developments and expected results of operations**

Based on the long term trend of women in Australia delaying the birth of children and the fertility rate among Australian women aged over 30 continuing to increase as a consequence of a range of social and economic demographic factors, we expect that demand for assisted reproductive services and the associated diagnostic testing and day hospital procedures will continue to increase.

We will continue to invest in our network of fertility clinics and also the clinical and scientific services offered to patients to enable the consolidated entity to meet the demand from the Australian market. Additionally we will consider further investment in our international network of fertility clinics.

#### **Business Risks**

The consolidated entity is faced with certain material business risks that could have an effect on the financial prospects of the consolidated entity. These include:

*Change in Commonwealth Government funding/increasing patient out of pocket expenses*

Patients receive partial reimbursement for the consolidated entity's services through Commonwealth Government programs, including the Medicare Benefits Schedule ('MBS') and the Extended Medicare Safety Net ('EMSN'). We anticipate that each of these programs will be reviewed during 2015.

If the level of reimbursement provided by these programs for the consolidated entity's services were to change, the consolidated entity's patients may face higher out-of-pocket expenses for Assisted Reproductive Services. This may cause the consolidated entity to experience reduced demand for its range of services, potentially leading to a reduction in the consolidated entity's revenue and profitability.

*Availability of fertility specialists*

The consolidated entity relies on maintaining its relationship with existing fertility specialists, as well as contracting with and growing In-Vitro Fertilisation ('IVF') cycles for new fertility specialists to assist in capturing market growth, increasing market share and replacing any retiring fertility specialists. If the consolidated entity cannot successfully maintain its relationship with existing fertility specialists or contract and grow IVF cycles for new fertility specialists this may cause the consolidated entity to experience reduced demand for its range of services, potentially leading to a reduction in the consolidated entity's revenue and profitability.

*Variability of growth*

The growth in patient demand and IVF cycles has historically experienced variability over short-term periods notwithstanding the long-term social and demographic trends driving patient demand for Assisted Reproductive Services. Variability in the historic growth in IVF cycles over short-term periods has been attributable to changes in local economic conditions, natural disasters and regulatory changes. Whilst Virtus is diversified across regional markets, the consolidated entity's revenue generation and profitability can be positively and negatively affected in the short term by variability in the growth in IVF cycles in the regional markets in which it operates.

*Increased competition*

The consolidated entity may face increased competition from new IVF providers and this may cause the consolidated entity to experience reduced demand for its range of services, potentially leading to a reduction in the consolidated entity's revenue and profitability.

**Environmental regulation**

The consolidated entity is not subject to any significant environmental regulation under Australian Commonwealth or State law.

**Information on directors**

Name:	Peter Macourt
Title:	Chairman
Qualifications:	BCom.; ACA; GAICD
Experience and expertise:	Peter is a former director and Chief Operating Officer of News Limited. Whilst at News Limited, he served as a director of Premier Media, Foxtel, Independent Newspapers Limited and a number of subsidiaries and associated companies of The News Corporation Limited.
Other current directorships:	Chairman of SKY Network Television Limited (since August 2002); Director of Prime Media Limited
Former directorships (last 3 years):	None
Special responsibilities:	Member of the Audit Committee and the Nomination and Remuneration Committee.
Interests in shares:	18,485 ordinary shares held directly
Interests in options:	None

**Name:** Susan Channon  
**Title:** Chief Executive Officer  
**Qualifications:** Registered Nurse Div1; OR Management Certificate  
**Experience and expertise:** Susan (Sue) has held senior management positions in various Australian healthcare organisations for over 20 years. Before her appointment to Chief Executive Officer ('CEO') of the company in November 2010, Sue was CEO of IVF Australia Pty Ltd. Prior to joining the company, Sue was State Manager for NSW and ACT for Medical Imaging Australia, the National Director of Nursing for Mayne Group (now part of Ramsay Health Care), CEO of Kareena Private Hospital, CEO of Castlecrag and Mosman Private Hospital and CEO and Director of Nursing for Castlecrag Private Hospital.

**Other current directorships:** None  
**Former directorships (last 3 years):** None  
**Special responsibilities:** Member of the Risk Committee  
**Interests in shares:** 448,633 ordinary shares  
**Interests in options:** 298,972 options over ordinary shares

**Name:** Dennis O'Neill  
**Title:** Non-Executive Director  
**Qualifications:** BSc. (Hons) Mech. Eng; CPE (ret), FIEA; FAICD; FAIM  
**Experience and expertise:** Dennis is the former Chief Executive Officer and Managing Director of Evans Deakin Industries Ltd and United Group Ltd and the former Chairman of Decmil Group Ltd. In March 2009 Dennis was appointed as Chairman and Advisory Chairman of Queensland Fertility Group Pty Ltd and stepped down as the Advisory Chairman in October 2014. He is also Advisory Chairman to several unlisted companies and was the Steel Supplier Advocate for the Commonwealth Government until 30 June 2014.

**Other current directorships:** None  
**Former directorships (last 3 years):** None  
**Special responsibilities:** Chair of the Audit Committee  
**Interests in shares:** 50,000 ordinary shares  
**Interests in options:** None

**Name:** Lyndon Hale  
**Title:** Executive Director  
**Qualifications:** MBBS; FRACOG; CREI  
**Experience and expertise:** Lyndon has been the Medical Director of Melbourne IVF Pty Ltd since 2008. He is also director of Reproductive Surgery at The Women's Hospital, and is on the board of the Fertility Society of Australia. Lyndon is highly regarded for his knowledge and proactive approach and brings extensive experience in assisted reproduction treatments to the care of his patients.

**Other current directorships:** None  
**Former directorships (last 3 years):** None  
**Special responsibilities:** None  
**Interests in shares:** 823,694 ordinary shares  
**Interests in options:** None

**Name:** Peter Turner  
**Title:** Non-Executive Director  
**Qualifications:** BSc.; MBA; GAICD  
**Experience and expertise:** Prior to joining the company, Peter served as Executive Director and Chief Operating Officer of CSL Limited and was the founding President of CSL Behring LLC. Peter is currently Chairman of NPS MedicineWise.

**Other current directorships:** Chairman, Ashley Services Group Ltd  
**Former directorships (last 3 years):** CSL Limited  
**Special responsibilities:** Chair of the Risk Committee and the Nomination and Remuneration Committee and member of the Audit Committee.  
**Interests in shares:** 50,000 ordinary shares  
**Interests in options:** None

Name:	Sonia Petering
Title:	Non-Executive Director
Qualifications:	LLB; BComm; FAICD
Experience and expertise:	Sonia is a corporate lawyer who brings extensive experience as a Director. She is currently Chair of the Rural Finance Corporation of Victoria and a Non-Executive Director of Victoria's Transport Accident Commission. Sonia is also a director of TAL, Dia-Ichi Life Australia Pty Limited.
Other current directorships:	None
Former directorships (last 3 years):	None
Special responsibilities:	Member of the Risk Committee and the Nomination and Remuneration Committee.
Interests in shares:	2,500 ordinary shares
Interests in options:	None

'Other current directorships' quoted above are current directorships for listed entities only and excludes directorships of all other types of entities, unless otherwise stated.

'Former directorships (in the last 3 years)' quoted above are directorships held in the last 3 years for listed entities only and excludes directorships of all other types of entities, unless otherwise stated.

### Company secretary

Glenn Powers joined Virtus as Chief Financial Officer ('CFO') and Company Secretary in August 2008. Prior to joining Virtus, Glenn was CFO and Company Secretary of Tower Software Limited. Glenn has a broad range of experience in private equity backed businesses, working in a range of engineering, electronics, software and service businesses. Glenn has also been a Director for both main and AIM market listed businesses in the UK. Glenn is a Chartered Management Accountant (CMA).

### Meetings of directors

The number of meetings of the company's Board of Directors ('the Board') and of each Board committee held during the year ended 30 June 2015, and the number of meetings attended by each director were:

	Full Board		Nomination and Remuneration Committee	
	Attended	Held	Attended	Held
Peter Macourt - Chairman	9	9	2	2
Marcus Darville	-	1	-	1
Susan Channon	8	9	-	-
Dennis O'Neill	9	9	-	-
Lyndon Hale	7	9	-	-
Peter Turner	9	9	2	2
Sonia Petering	8	8	1	1
	Audit Committee		Risk Committee	
	Attended	Held	Attended	Held
Peter Macourt - Chairman	4	4	-	-
Marcus Darville	1	1	-	-
Susan Channon	-	-	3	3
Dennis O'Neill	4	4	-	-
Peter Turner	4	4	3	3
Sonia Petering	-	-	3	3

Held: represents the number of meetings held during the time the director held office or was a member of the relevant committee.

### Remuneration report (audited)

The directors present the remuneration report, which outlines the key management personnel remuneration arrangements for the consolidated entity, in accordance with the requirements of the Corporations Act 2001 and its Regulations.

The information provided in this Remuneration report, which forms part of the Directors' report has been audited as required by Section 308(3C) of the Corporations Act 2001.

The remuneration report is set out under the following main headings:

- A. Principles used to determine the nature and amount of remuneration
- B. Details of remuneration
- C. Service agreements
- D. Share-based compensation
- E. Additional information
- F. Additional disclosures relating to key management personnel

#### ***A. Principles used to determine the nature and amount of remuneration***

The objective of the consolidated entity's executive reward framework is to ensure reward for performance is competitive and appropriate for the results delivered. The framework aligns executive reward with the achievement of strategic objectives and the creation of value for shareholders, and conforms to the market best practice for delivery of reward. The Board of Directors (the 'Board') ensures that executive reward satisfies the following key criteria for good reward governance practices:

- competitiveness and reasonableness
- acceptability to shareholders
- performance linkage / alignment of executive compensation
- transparency

The role of the Nomination and Remuneration Committee is to assist and advise the Board on the following nomination related matters:

- director selection, CEO selection and appointment practice;
- director performance evaluation processes and criteria;
- Board composition; and
- succession planning for the Board and senior executives.

In consultation with external remuneration consultants (refer to the section 'use of remuneration consultants' below), the Nomination and Remuneration Committee has structured an executive remuneration framework that is market competitive and complementary to the reward strategy of the consolidated entity. Key objectives of the remuneration framework are as follows:

Alignment to shareholders' interests; the framework:

- has economic profit as a major component of plan design;
- focuses on sustained growth in shareholder wealth, consisting of dividends and growth in share price, and delivering constant or increasing return on equity as well as focusing the executive on key non-financial drivers of value; and
- attracts and retains high calibre executives.

Alignment to program participants' interests; the framework:

- rewards capability and experience;
- reflects competitive reward for contribution to growth in shareholder wealth; and
- provides a clear structure for earning rewards.

In accordance with best practice corporate governance, the structure of non-executive directors' and executive remunerations are separate.

#### ***Non-executive directors remuneration***

Fees and payments to non-executive directors reflect the demands which are made on, and the responsibilities of, the directors. Non-executive directors' fees and payments are reviewed annually by the Nomination and Remuneration Committee. The Nomination and Remuneration Committee may, from time to time, receive advice from independent remuneration consultants to ensure non-executive directors' fees and payments are appropriate and in line with the market. The Chairman's fees are determined independently to the fees of other non-executive directors based on comparative roles in the external market. The Chairman is not present at any discussions relating to determination of his own remuneration. Non-executive directors do not receive share options or other incentives.

Under the Constitution, the directors decide the total amount paid to each director as remuneration for their services as a director to the company. However, under the listing rules of the ASX ('ASX Listing Rules'), the total amount paid to all non-executive directors for their services must not exceed in aggregate in any financial year the amount approved by the shareholders. This amount has been fixed at \$500,000 with effect from 17 May 2013. Aggregate annual directors' fees paid to directors in the financial year ending 30 June 2015 were \$420,331; details of the fees payable to each director are set out in the section B. A shareholder resolution will be submitted at the Annual General Meeting recommending an increase in the total amount payable to all non-executive directors for their services from \$500,000 to \$600,000.

All directors' fees include superannuation at the superannuation guarantee rate for the respective amounts.

#### *Executive remuneration*

The executive remuneration and reward framework has four components:

- base pay and non-monetary benefits;
- short-term performance incentives;
- long-term performance incentives; and
- other remuneration such as superannuation and long service leave.

The combination of these comprises the executive's total remuneration.

Fixed remuneration, consisting of base salary, superannuation and non-monetary benefits, are reviewed annually by the Nomination and Remuneration Committee, based on individual and business unit performance, the overall performance of the consolidated entity and comparable market remunerations.

Executives may receive their fixed remuneration in the form of cash or other fringe benefits (for example motor vehicle benefits) where it does not create any additional costs to the consolidated entity and provides additional value to the executive.

#### *Short-term incentives*

The short-term incentives ('STI') program is designed to align the targets of the business units with the targets of those executives in charge of meeting those targets. STI payments are granted to executives based on specific annual targets and key performance indicators ('KPI's') being achieved. KPI's include EBIT performance at group and territory level, volume growth in territory, cost management targets and individual management and business development objectives.

Based on the achievements of Virtus Health Limited, this year the Nomination and Remuneration Committee determined that that executives had achieved the following percentages of their targets:

- Susan Channon - 50%
- Glenn Powers - 55%
- Andrew Othen - 33%
- Steve Zappia - 33%
- Nadia Stankovic - 58%
- Anthony Walsh - no target was set as Mr. Walsh is incentivised to enhance shareholder value by way of his minority shareholder interest in the business performance of Sims IVF.

In making this assessment the Nomination and Remuneration Committee considered the following factors:

- EBIT target achievements;
- Volume growth achievement;
- Cost management achievement; and
- Acquisitions.

Each of the targets above are measurable in financial terms. 40%-60% of the annual STI is payable in relation to the achievement of the financial year EBIT targets which are established by the Nomination and Remuneration Committee on an annual basis. Other operational KPIs account for the remainder of the STI.

Financial and non-financial KPIs are reviewed and amended annually by the Nomination and Remuneration Committee to ensure STI payments are aligned with the short term objectives of the business.



#### *Long-term benefits*

The long-term benefits ('LTB') include long service leave accruals and share-based incentives. Performance rights are awarded to executives at the end of a period of three years based on the achievement of certain vesting conditions. These include increase in shareholder return relative to the entire market and the increase compared to the consolidated entity's industry peers. The Nomination and Remuneration Committee reviewed the long-term equity-linked performance incentives specifically for executives during the year ended 30 June 2015.

Performance rights will vest and become exercisable to the extent that the applicable performance, service, or other vesting conditions specified at the time of the grant are satisfied. Vesting conditions may include conditions relating to continuous employment or service, the individual performance of the participant in the plans or the company's performance.

The Board has the discretion to set the terms and conditions on which it will offer performance rights under the plans, including the vesting conditions and different terms and conditions which apply to different participants in a plan.

Upon the satisfaction of the vesting conditions and any other conditions to exercise, each performance right will convert to a number of shares based on the terms of issue of the performance rights. Performance rights granted to employees, including executive directors, will typically convert on a one-for-one basis.

Participants may be required to pay an exercise price to exercise the performance rights which is based on the market price of shares at or around the time of the grant of the options. The plans also include flexibility to allow the company to grant options with no exercise price. Participants will not need to pay any money to be granted options under the plans.

#### *Consolidated entity performance and link to remuneration*

Remuneration for certain individuals is directly linked to performance of the consolidated entity. A portion of bonus and incentive payments are dependent on defined earnings per share targets being met.

#### *Use of remuneration consultants*

The Nomination and Remuneration Committee engaged KPMG to provide recommendations on the following matters:

- Long term incentive performance hurdles;
- Executive remuneration benchmarking; and
- Non-executive director fees benchmarking

The total consideration payable to KPMG for the advice provided was \$24,000 excluding GST.

The scope of the report and all discussions with KPMG were undertaken by the Chairman of the Nomination and Remuneration Committee, Peter Turner, in consultation with the independent directors, Peter Macourt, Chairman, and Sonia Petering who are both members of the Nomination and Remuneration Committee. No discussions were held between KPMG and the CEO, CFO or other key management personnel. Accordingly the Board is satisfied that the recommendations made by KPMG are free from undue influence by any member of the key management personnel to whom the recommendations relate.

The Chairman of the Nomination and Remuneration Committee is also satisfied that the recommendation relating to non-executive director fees, including the fees for the Chairman, has not been subject to any undue influence by the Chairman or other independent directors.

#### *Other information about directors' remuneration*

Directors may also be reimbursed for expenses reasonably incurred in attending to the company's affairs. Non-executive directors may be paid such additional or special remuneration as the directors decide is appropriate where a director performs extra work or services which are not in the capacity as a director of the company or a subsidiary. There is no contractual redundancy benefit for directors.

#### *Share option plans*

The company has adopted an option plan ('Plan') to assist in the reward, motivation and retention of personnel (including executive directors, eligible employees and fertility specialists). The Plan is also designed to recognise the abilities, efforts and contributions of participants to Virtus' performance and success and provide the participants with an opportunity to acquire or increase their ownership interest in the company.

The Plan contemplates the grant of options over shares. There is no ability for the company to provide any cash equivalent on exercise.



#### *Eligibility*

Eligibility to participate in the Plans and the number of options offered to each individual participant will be determined by the Board.

#### *Grants of options or performance rights - Senior executives and employees*

It is expected that options or performance rights may be granted to certain senior executives of the company on an annual basis as part of their annual remuneration review. Generally, vesting conditions attaching to grants of options or performance rights made to senior executives will relate to the performance of the company over the performance period as well as continued employment. Options may also be granted to other employees from time to time subject to consideration by the Board.

#### *Senior executives - 2013 grant*

Susan Channon and Glenn Powers were granted options under the prospectus at the time of Listing. The key terms and conditions attaching to that grant of options are set out below.

The options granted to Susan Channon and Glenn Powers are in two tranches, with each tranche subject to two separate vesting conditions which are both based on external measures as follows:

- The hurdle for 50% of the options is based on a share price hurdle which measures the growth in the company's share price over a three year performance period. The number of options that vest will depend on the share price growth ('SPG') of shares over the performance period. The SPG is determined by subtracting the share price at the beginning of the performance period from the share price at the end of the performance period, and dividing that figure by the share price at the beginning of the performance period. No options will vest at growth below 15%. 50% will vest at 15% growth and vesting thereafter will be determined on a straight-line scale with 100% vesting at 50% growth.
- The hurdle for the remaining 50% of the options is based on the company's total shareholder return ('TSR') relative to a peer group of companies in both the S&P ASX 300 Index and the S&P ASX 300 Healthcare Index (weighted 50% each) over the three year performance period. No options will vest if the TSR performance is less than the 50th percentile. 50% of the options will vest at median (i.e. the 50th percentile) TSR performance and vesting thereafter will be determined on a straight-line scale with 100% vesting if the TSR performance is greater than or equal to the 75th percentile. TSR is a measure of the return on investment in a company's shares, including dividends and all other returns to shareholders notionally invested over the relevant performance period.

The performance hurdles for each tranche of options are not interdependent, meaning that it is possible for one tranche to vest while the other does not vest. In each case, the performance hurdles will only be measured once and there will be no retesting. Importantly, no value will be received by Susan Channon or Glenn Powers if the performance hurdles are not met and the options do not vest.

The vesting of the options is also subject to continued service by the relevant executive over the relevant performance period.

#### *Senior executives - 2014 grant*

On 10 November 2014, performance rights were granted to the following members of the executive management team:

Sue Channon;  
Glenn Powers  
Andrew Othen;  
Nadia Stankovic;  
Steve Zappia; and  
Anthony Walsh.

The main features of the performance rights are set out below. The performance rights vest subject to the following performance hurdles:

- The performance hurdles for the Plan are relative total shareholder return (TSR) and earnings per share (EPS) growth. Each hurdle applies to 50% of the grant. TSR is measured on the Company's TSR relative to a peer group of companies in both the S&P ASX 200 Index and the S&P ASX 200 Healthcare Index (weighted 50% each) over the three year performance period. TSR is a measure of the return on investment in a company's shares, including dividends and all other returns to shareholders notionally invested over the relevant performance period.

- The percentage of the TSR Component which may vest is based on a sliding scale as follows:
  - o 0% if the TSR does not reach the 50th percentile of the TSRs of the S&P/ASX 200 index and the S&P ASX 200 Healthcare index (weighted 50% each)
  - o 50% if the TSR reaches the 50th percentile of the TSRs of the S&P/ASX 200 index and the S&P ASX 200 Healthcare index (weighted 50% each)
  - o Progressive rate (straight-line) vesting from 50% to 100% if the TSR exceeds the 50th percentile of the TSRs of the S&P/ASX 200 index and the S&P ASX 200 Healthcare index (weighted 50% each) but does not reach the 75th percentile
  - o 100% if the TSR reaches or exceeds the 75th percentile of the TSRs of the S&P/ASX 200 index and the S&P ASX 200 Healthcare index (weighted 50% each)
- The percentage of the EPS growth component which may vest is based on a sliding scale as follows:
  - o 0% if the compound average growth rate ("CAGR") does not reach 7.5%;
  - o 50% if the CAGR reaches 7.5%;
  - o Progressive rate (straight-line) vesting from 50% to 100% if the CAGR exceeds 7.5% but does not reach 10%; and
  - o 100% if the CAGR reaches or exceeds 10%

Calculations of the Company's TSR and EPS will be determined at the end of the three year vesting period and approved by the Board.

#### *Grants of options - fertility specialists*

Options will be granted on an annual basis to existing fertility specialists who achieve a benchmark level of IVF Cycles above a base or adjusted base number of IVF cycles established in one of the financial years ending after June 2008, up to June 2015.

In addition, consistent with the practice pre-Listing on the ASX, options will also be granted to new fertility specialists upon commencing a contractual relationship with the company post-Listing. The initial benchmark level for new fertility specialists is 50 IVF Cycles and subsequent benchmark levels are at each 50 cycle increment thereafter.

The key terms and conditions to these option grants are set out below:

For existing fertility specialists, options will generally vest equally in three tranches on the third, fourth and fifth anniversary of the grant of the options, conditional upon the fertility specialist performing a number of IVF Cycles in the immediately preceding year not less than 75% of the relevant benchmark in the year pursuant to which the options were awarded.

For new fertility specialists who join the company, options will generally vest equally in three tranches on the third, fourth and fifth anniversary of the grant of the options, subject to:

- the fertility specialist achieving the relevant benchmark (currently 50 IVF Cycles) in a 12 month period during the two years post commencement of the contractual relationship with Virtus and concurrent grant of options; and
- the fertility specialist then achieving a number of IVF Cycles in the year before the relevant vesting date that is not less than 75% of the benchmark number.

In addition, an option may not be exercised unless it is "in the money" (i.e. if the share price at the relevant time is greater than the share price at the time of the option grant).

#### *Vesting Conditions*

Options will vest and become exercisable to the extent that the applicable performance, service, or other Vesting Conditions specified at the time of the grant are satisfied. Vesting Conditions may include conditions relating to continuous employment or service, the individual performance of the participant in the Plan or the company's performance.

The Board has the discretion to set the terms and conditions on which it will offer options under the Plan, including the Vesting Conditions and different terms and conditions which apply to different participants in the Plan.

Upon the satisfaction of the Vesting Conditions and any other conditions to exercise, each option will be exercisable into a variable number of shares based on the terms of issue of the options. The number of shares to be issued will be calculated by multiplying the applicable component of the offer value of the grant by the amount of the increase in the share price between the share price at vesting compared to the price at grant all divided by the share price at vesting.

Participants will not need to pay any money to be granted options under the Plans.

*High performance options – fertility specialists*

The Virtus Board wishes to recognise those Fertility Specialists that achieve a high level of fresh cycles over a defined period acknowledging the value they generate for all stakeholders. The Board has created a High Performer Share Incentive Scheme to reward Fertility Specialists who consistently deliver more than 400 cycles per annum for a consecutive three year period.

The structure for such an incentive is set out below:

The High Performer incentive will have a performance hurdle whereby Fertility Specialists are required to achieve fresh cycle activity at greater than or equal to 400 cycles per annum over a consecutive three year qualifying period; The first incentive period commenced on 1 January 2014 and will run for a three year period ending 31st December 2016;

Three fertility specialists currently meet the performance criteria after one year of the qualifying period and the base price at date of grant is \$8.69 with a base value of the incentive value of \$500,000;

The first vesting date is 1 January 2017 and vesting is also dependent on the ordinary share price at exercise being higher than the base price set at the time of incentive commencement;

- The actual number of vested options awarded will be in accordance with the calculation methodology applied to the Fertility Specialist performance incentive structure;
- Performance option grants may still be accrued for incremental performance above 400 cycles.
- Once a vesting award is achieved after three years of consecutive high performance, a Fertility Specialist may then commence a new three year high performer incentive period. For example in a six year period a Fertility Specialist may achieve 2 vested awards with a base value of \$500,000 each if he/she achieves 400 cycles per annum for a consecutive period of 6 years.
- The 2015-2017 high performer share incentive commenced on 1 January 2015 for all eligible Fertility Specialists who did not achieve 400 cycles in calendar year 2014. The base price at date of grant was the average daily closing share price for the month ending 31 December 2014.
- The high performer share incentive is administered in accordance with the plan rules established in the Virtus Health Limited Specialist Option Plan approved by the Board in June 2013.

The second incentive period commenced on 1 January 2015 and will run for a three year period ending 31 December 2017 and the base price at the date of grant is \$7.42 with a base incentive value of \$500,000.

*Ranking of shares*

Shares issued upon exercise of options granted under the Plan will rank equally with the other issued shares.

*Voting and dividend rights*

Options do not carry any voting or dividend rights. Shares issued or transferred to participants on exercise of an option carry the same rights and entitlements as other issued shares, including dividend and voting rights.

*Approval*

Grants of options under the Plan to directors may be subject to the approval of shareholders, to the extent required under the ASX Listing Rules.

*Issue or acquisition of shares*

Shares allocated to participants in the Plan on the exercise of options may be issued by Virtus or acquired on or off market by the company or its nominee. The company may appoint a trustee to acquire and hold shares on behalf of participants or otherwise for the purposes of the Plan.

*No transfer of options*

Without the prior approval of the Board, options may not be sold, transferred, encumbered or otherwise dealt with. Further, participants cannot enter into any transaction, scheme or arrangement which hedges or otherwise affects the participant's economic exposure to the options before they vest.

*Lapse of options*

Options will lapse if the applicable vesting conditions and any other conditions to exercise are not met during the prescribed period or if they are not exercised before the applicable expiry date.

## **B. Details of remuneration**

### *Amounts of remuneration*

Details of the remuneration of key management personnel of the consolidated entity are set out in the following tables.

The key management personnel of the consolidated entity consisted of the directors of Virtus Health Limited and the following persons:

- Glenn Powers – Group Chief Financial Officer and Company Secretary
- Nadia Stankovic – Managing Director, New South Wales
- Andrew Othen – Managing Director, Victoria
- Steve Zappia – Managing Director, Queensland
- Anthony Walsh – Managing Director, Ireland
- William Watkins – Medical Director, Tasmania
- Peter Illingworth – Medical Director, New South Wales
- David Molloy – Medical Director, Queensland

	Short-term benefits			Post-employment benefits	Long-term benefits	Share-based payments	
	Cash salary and fees	Bonus	Non-monetary and termination	Super-annuation	Employee leave	Equity-settled	Total
2015	\$	\$	\$	\$	\$	\$	\$
<i>Non-Executive Directors:</i>							
P Macourt	132,991	-	-	12,634	-	-	145,625
D O'Neill	84,246	-	-	8,003	-	-	92,249
P Turner	100,228	-	-	9,521	-	-	109,749
S Petering	66,400	-	-	6,308	-	-	72,708
<i>Executive Directors:</i>							
S Channon	470,857	85,000	-	36,966	11,078	147,593	751,494
L Hale	75,000	-	-	-	-	-	75,000
<i>Other Key Management Personnel*:</i>							
G Powers	331,622	60,500	-	37,521	6,947	89,520	526,110
N Stankovic	254,800	46,617	-	27,770	4,576	13,467	347,230
A Othen	290,638	28,189	-	30,199	9,050	16,699	374,775
S Zappia	257,013	27,337	-	26,590	966	13,750	325,656
A Walsh	158,026	-	-	-	-	5,211	163,237
P Illingworth	177,290	-	-	-	-	-	177,290
D Molloy	80,126	-	-	-	-	-	80,126
	<u>2,479,237</u>	<u>247,643</u>	<u>-</u>	<u>195,512</u>	<u>32,617</u>	<u>286,240</u>	<u>3,241,249</u>

\* William Watkins did not receive any remuneration in his capacity as a key management person in the financial year ending 30 June 2015

Marcus Darville agreed to provide his services to Virtus for no salary or fee for the period of his directorship up until his date of resignation.

	Short-term benefits			Post-employment benefits	Long-term benefits	Share-based payments	
	Cash salary and fees	Bonus	Non-monetary	Super-annuation	Employee leave	Equity-settled	Total
2014	\$	\$	\$	\$	\$	\$	\$
<i>Non-Executive Directors:</i>							
P Macourt	129,291	-	-	11,959	-	-	141,250
D O'Neill*	109,040	-	-	7,620	-	-	116,660
P Turner	84,668	-	-	7,832	-	-	92,500
<i>Executive Directors:</i>							
S Channon	440,008	78,275	-	24,992	26,146	110,149	679,570
L Hale	75,000	-	-	-	-	-	75,000
<i>Other Key Management Personnel:</i>							
G Powers	305,000	47,975	-	25,010	6,156	62,943	447,084
B Ayres	73,964	-	52,929	10,934	-	-	137,827
N Stankovic	9,100	-	-	842	340	-	10,282
A Othen	283,197	40,547	-	31,489	7,543	-	362,776
S Zappia	236,748	20,091	-	21,797	353	-	278,989
P Illingworth	176,288	-	-	-	-	-	176,288
D Molloy	79,943	-	-	-	-	-	79,943
	2,002,247	186,888	52,929	142,475	40,538	173,092	2,598,169

\* Dennis O'Neill received fees of \$26,660 in the financial year ending 30 June 2014 in respect of his role as Advisory Chairman of Queensland Fertility Group Pty Ltd.; the role ceased in October 2013.

\*\* Marcus Darville agreed to provide his services to Virtus for no salary or fee for the period of his directorship following the IPO in June 2013.

The following key management personnel received provider fees for IVF services delivered to patients: Lyndon Hale, David Molloy, Peter Illingworth and William Watkins. Details are disclosed in note 38 to the financial report.

The proportion of remuneration linked to performance and the fixed proportion are as follows:

Name	Fixed remuneration		At risk - STI		At risk - LTI	
	2015	2014	2015	2014	2015	2014
<i>Non-Executive Directors:</i>						
P Macourt	100%	100%	-%	-%	-%	-%
D O'Neill	100%	100%	-%	-%	-%	-%
P Turner	100%	100%	-%	-%	-%	-%
S Petering	100%	-%	-%	-%	-%	-%
<i>Executive Directors:</i>						
S Channon	69%	72%	11%	12%	20%	16%
L Hale	100%	100%	-%	-%	-%	-%
<i>Other Key Management Personnel:</i>						
G Powers	72%	75%	11%	11%	17%	14%
B Ayres	-%	100%	-%	-%	-%	-%
A Othen	88%	89%	8%	11%	4%	-%
N Stankovic	83%	100%	13%	-%	4%	-%
S Zappia	87%	93%	9%	7%	4%	-%
A Walsh	97%	-%	-%	-%	3%	-%
P Illingworth	100%	100%	-%	-%	-%	-%
D Molloy	100%	100%	-%	-%	-%	-%

The proportion of the cash bonus paid/payable or forfeited is as follows:

Name	Cash bonus paid/payable		Cash bonus forfeited	
	2015	2014	2015	2014
<i>Executive Directors:</i>				
S Channon	50%	51%	50%	49%
<i>Other Key Management Personnel:</i>				
G Powers	55%	51%	45%	49%
A Othen	33%	49%	67%	51%
S Zappia	33%	25%	67%	75%
N Stankovic	58%	-%	42%	-%

### **C. Service agreements**

Remuneration and other terms of employment for key management personnel are formalised in service agreements. Details of these agreements are as follows:

Name:	Lyndon Hale
Title:	Executive Director
Agreement commenced:	11 June 2013
Term of agreement:	No fixed end date
Details:	The executive may terminate their fertility specialist contract by giving a minimum of six months' notice or maximum of twelve months' notice in writing. The company may terminate by giving 12 months' notice in writing. Upon the termination of the fertility specialist contract, the fertility specialist will be subject to a restraint of trade period of 12 months. The company may elect to reduce the restraint of trade period, or eliminate the period in its entirety. The enforceability of the restraint clause is subject to all usual legal requirements.

Name: Susan Channon  
Title: Chief Executive Officer  
Agreement commenced: 11 June 2013  
Term of agreement: No fixed end date  
Details: The executive may terminate the employment contract by giving three months' notice in writing. The company may terminate by giving 12 months' notice in writing or by making a payment in lieu of notice. In the event of serious misconduct or other specific circumstances warranting summary dismissal, the company may terminate the employment contract immediately by notice in writing and without payment in lieu of notice. Upon the termination of the employment contract, the executive will be subject to a restraint of trade period of 12 months. The company may elect to reduce the restraint of trade period, or eliminate the period in its entirety. The enforceability of the restraint clause is subject to all usual legal requirements.

Name: Glenn Powers  
Title: Chief Financial Officer and Company Secretary  
Agreement commenced: 11 June 2013  
Term of agreement: No fixed end date  
Details: The executive may terminate the employment contract by giving three months' notice in writing. The company may terminate by giving six months' notice in writing or by making a payment in lieu of notice. In the event of serious misconduct or other specific circumstances warranting summary dismissal, the company may terminate the employment contract immediately by notice in writing and without payment in lieu of notice. Upon the termination of the employment contract, the executive will be subject to a restraint of trade period of 12 months. The company may elect to reduce the restraint of trade period, or eliminate the period in its entirety. The enforceability of the restraint clause is subject to all usual legal requirements.

#### Other Key Management Personnel

Each of the company's state managing directors, Andrew Othen, Steve Zappia, Nadia Stankovic and Anthony Walsh are employed under individual executive services agreements. These establish:

- total compensation including a base salary, superannuation contribution and incentive arrangements;
- variable notice and termination provisions of up to six months;
- confidentiality provisions;
- leave entitlements, as a minimum, as per the National Employment Standard; and
- restraint provisions.

The company's state medical directors, Peter Illingworth, David Molloy and William Watkins are contracted under fertility specialist agreements. The Executive may terminate their fertility specialist contract by giving a minimum of six months' notice or maximum of twelve months' notice in writing. The company may terminate by giving 12 months' notice in writing and upon the termination of the fertility specialist contract the fertility specialist will be subject to a restraint of trade period of 12 months. The company may elect to reduce the restraint of trade period, or eliminate the period in its entirety. The enforceability of the restraint clause is subject to all usual legal requirements.

Key management personnel have no entitlement to termination payments in the event of removal for misconduct.

#### ***D. Share-based compensation***

##### *Issue of shares*

There were no shares issued to directors and other key management personnel as part of compensation during the year ended 30 June 2015.



### Options

The terms and conditions of each grant of options over ordinary shares affecting remuneration of directors and other key management personnel in this financial year or future reporting years are as follows:

Grant date	Vesting date and exercisable date	Expiry date	Exercise price	Fair value per option at grant date
11 June 2013	11 June 2016	11 June 2018	\$5.68	\$1.26
11 June 2013	27 February 2014	27 January 2017	\$5.68	\$1.43
10 November 2014	10 November 2017	10 November 2024	\$0.00	\$1.24

Options do not carry any voting or dividend rights. Shares issued or transferred to participants on exercise of an option carry the same rights and entitlements as other issued shares, including dividend and voting rights.

Refer to section A of this remuneration report for details of the option plan.

The number of options over ordinary shares granted to and vested by directors and other key management personnel as part of compensation during the year ended 30 June 2015 are set out below:

Name	Number of options granted during the year 2015	Number of options granted during the year 2014	Number of options vested during the year 2015	Number of options vested during the year 2014
Susan Channon	36,472	-	-	-
Glenn Powers	25,888	-	-	-
Andrew Othen	16,266	135,397	-	135,397
Nadia Stankovic	13,118	-	-	-
Steve Zappia	13,393	-	-	-
Anthony Walsh	5,076	-	-	-
Peter Illingworth	-	50,000	-	50,000

Values of options over ordinary shares granted, exercised and lapsed for directors and other key management personnel as part of compensation during the year ended 30 June 2015 are set out below:

Name	Value of options granted during the year \$	Value of options exercised during the year \$	Value of options lapsed during the year \$
Susan Channon	251,657	-	-
Glenn Powers	178,627	-	-
Andrew Othen	112,235	-	-
Nadia Stankovic	90,514	-	-
Steve Zappia	92,412	-	-
Anthony Walsh	35,024	-	-

Value of options exercised during the year includes options cancelled during the year.



### **E. Additional information**

The earnings of the consolidated entity for the five years to 30 June 2015 are summarised below:

	2015 \$'000	2014 \$'000	2013 \$'000	2012 \$'000	2011 \$'000
Sales revenue	233,696	201,249	186,581	165,119	127,197
EBITDA*	61,355	59,404	43,429	48,708	40,510
EBIT	51,361	51,212	34,684	39,736	32,233
Profit after income tax	30,441	30,957	10,104	19,660	15,337

\* EBITDA 2013 is stated before deduction of initial public offering costs.

The factors that are considered to affect total shareholders return ('TSR') are summarised below:

	2015	2014	2013	2012*	2011*
Share price at financial year end (\$)	5.37	8.16	6.45	-	-
Total dividends declared (cents per share)	27.00	12.00	133.50	-	-
Basic earnings per share (cents per share)	36.05	38.80	17.78	36.73	-
Diluted earnings per share (cents per share)	35.75	38.48	16.78	34.22	-

\* Share price is not applicable for the years 2011 to 2012 as the company was not a listed entity in these years.

### **F. Additional disclosures relating to key management personnel**

In accordance with Class Order 14/632, issued by the Australian Securities and Investments Commission, relating to 'Key management personnel equity instrument disclosures', the following disclosures relate only to equity instruments in the Company or its subsidiaries.

#### **Shareholding**

The number of shares in the company held during the financial year by each director and other members of key management personnel of the consolidated entity, including their personally related parties, is set out below:

	Balance at the start of the year	Received as part of remuneration	Additions	Disposals/ other	Balance at the end of the year
<b>Ordinary shares</b>					
Peter Macourt	18,485	-	-	-	18,485
Susan Channon	448,633	-	-	-	448,633
Dennis O'Neill	50,000	-	-	-	50,000
Lyndon Hale	823,694	-	-	-	823,694
Peter Turner	50,000	-	-	-	50,000
Glenn Powers	114,150	-	-	-	114,150
Peter Illingworth	654,023	-	-	-	654,023
David Molloy	400,628	-	-	-	400,628
Sonia Petering	-	-	2,500	-	2,500
	<u>2,559,613</u>	<u>-</u>	<u>2,500</u>	<u>-</u>	<u>2,562,113</u>

### *Option holding*

The number of options over ordinary shares in the company held during the financial year by each director and other members of key management personnel of the consolidated entity, including their personally related parties, is set out below:

	Balance at the start of the year	Granted	Exercised/ cancelled	Expired/ forfeited/ other	Balance at the end of the year
<i>Options over ordinary shares</i>					
Susan Channon	262,500	36,472	-	-	298,972
Andrew Othen	38,000	16,266	-	-	54,266
Glenn Powers	150,000	25,888	-	-	175,888
Peter Illingworth	50,000	-	-	-	50,000
Nadia Stankovic	-	13,118	-	-	13,118
Steve Zappia	-	13,393	-	-	13,393
Anthony Walsh	-	5,076	-	-	5,076
	500,500	110,213	-	-	610,713

***This concludes the remuneration report, which has been audited.***

### **Shares under option**

Unissued ordinary shares of Virtus Health Limited under option at the date of this report are as follows:

Grant date	Expiry date	Exercise or base price	Number under option or shares to be issued
11 June 2013	11 June 2018	\$5.68	412,500
28 January 2014*	27 January 2017	\$5.68	263,005
20 January 2014**	20 January 2024	\$0.00	45,136
21 January 2014**	21 January 2024	\$8.49	-
21 January 2014**	21 January 2024	\$0.00	96,238
01 January 2014**	01 January 2024	\$8.69	29,073
03 October 2014**	03 October 2024	\$8.57	117,251
10 November 2014	10 November 2024	\$0.00	85,990
13 May 2015**	13 May 2025	\$7.16	7,372
13 May 2015**	13 May 2025	\$7.53	912
13 May 2015**	13 May 2025	\$7.94	794
13 May 2015**	13 May 2025	\$7.96	343
13 May 2015**	13 May 2025	\$8.01	262
			<u>1,058,876</u>

\* The consolidated entity agreed to issue 450,000 options to fertility specialists and 174,082 options to management as part of the IPO listing. Rights to these options were confirmed on 11 June 2013, and the options were formally granted 28 January 2014. For compliance with AASB 2 'Share-based Payment' it is assumed that 11 June 2013 is the grant date for these options.

\*\* The consolidated entity grants performance rights to fertility specialists as a dollar value; for the purpose of calculating the estimated number of shares under option, estimates of the share price at the time of vesting are forecast to facilitate an estimate of the number of shares to be issued at vesting.

No person entitled to exercise the options had or has any right by virtue of the option to participate in any share issue of the company or of any other body corporate.

### **Shares issued on the exercise of options**

During the financial year 175,000 ordinary shares were issued on the exercise of options. No share options were cancelled during the financial year. There were no shares of Virtus Health Limited issued on the exercise of options from 1 July 2015 up to and including the date of this report.

### **Indemnity and insurance of officers**

The company has indemnified the directors and executives of the company for costs incurred, in their capacity as a director or executive, for which they may be held personally liable, except where there is a lack of good faith.

During the financial year, the company paid a premium of \$112,000 in respect of a contract to insure the directors and executives of the company against a liability to the extent permitted by the Corporations Act 2001.

### **Indemnity and insurance of auditor**

The company has not, during or since the financial year, indemnified or agreed to indemnify the auditor of the company or any related entity against a liability incurred by the auditor.

During the financial year, the company has not paid a premium in respect of a contract to insure the auditor of the company or any related entity.

### **Proceedings on behalf of the company**

No person has applied to the Court under section 237 of the Corporations Act 2001 for leave to bring proceedings on behalf of the company, or to intervene in any proceedings to which the company is a party for the purpose of taking responsibility on behalf of the company for all or part of those proceedings.

### **Non-audit services**

Details of the amounts paid or payable to the auditor for non-audit services provided during the financial year by the auditor are outlined in note 35 to the financial statements.

The directors are satisfied that the provision of non-audit services during the financial year, by the auditor (or by another person or firm on the auditor's behalf), is compatible with the general standard of independence for auditors imposed by the Corporations Act 2001.

The directors are of the opinion that the services as disclosed in note 35 to the financial statements do not compromise the external auditor's independence requirements of the Corporations Act 2001 for the following reasons:

- all non-audit services have been reviewed and approved to ensure that they do not impact the integrity and objectivity of the auditor; and
- none of the services undermine the general principles relating to auditor independence as set out in APES 110 Code of Ethics for Professional Accountants issued by the Accounting Professional and Ethical Standards Board, including reviewing or auditing the auditor's own work, acting in a management or decision-making capacity for the company, acting as advocate for the company or jointly sharing economic risks and rewards.

### **Officers of the company who are former partners of PricewaterhouseCoopers**

There are no officers of the company who are former partners of PricewaterhouseCoopers.

### **Rounding of amounts**

The company is of a kind referred to in Class Order 98/100, issued by the Australian Securities and Investments Commission, relating to 'rounding-off'. Amounts in this report have been rounded off in accordance with that Class Order to the nearest thousand dollars, or in certain cases, the nearest dollar.

### **Auditor's independence declaration**

A copy of the auditor's independence declaration as required under section 307C of the Corporations Act 2001 follows this report.

### **Auditor**

PricewaterhouseCoopers continues in office in accordance with section 327 of the Corporations Act 2001.

This report is made in accordance with a resolution of directors, pursuant to section 298(2)(a) of the Corporations Act 2001.

On behalf of the directors

A handwritten signature in blue ink, appearing to read "Peter Macourt".

---

Peter Macourt  
Chairman

25 August 2015  
Sydney



## Auditor's Independence Declaration

As lead auditor for the audit of Virtus Health Limited for the year ended 30 June 2015, I declare that to the best of my knowledge and belief, there have been:

- a) no contraventions of the auditor independence requirements of the *Corporations Act 2001* in relation to the audit; and
- b) no contraventions of any applicable code of professional conduct in relation to the audit.

This declaration is in respect of Virtus Health Limited and the entities it controlled during the period.

A handwritten signature in cursive script that reads 'Eddie Wilkie'.

Eddie Wilkie  
Partner  
PricewaterhouseCoopers

Sydney  
25 August 2015

## **Contents**

Statement of comprehensive income	24
Statement of financial position	25
Statement of changes in equity	26
Statement of cash flows	27
Notes to the financial statements	28
Directors' declaration	76
Independent auditor's report to the members of Virtus Health Limited	77

## **General information**

The financial report consists of the financial statements, notes to the financial statements and the directors' declaration.

Virtus Health Limited is a listed public company limited by shares, incorporated and domiciled in Australia. Its registered office and principal place of business is:

Level 3  
176 Pacific Highway  
Greenwich NSW 2065

A description of the nature of the consolidated entity's operations and its principal activities are included in the directors' report, which is not part of the financial statements.

The financial statements were authorised for issue, in accordance with a resolution of directors, on 25 August 2015. The directors have the power to amend and reissue the financial statements.

**Virtus Health Limited**  
**Statement of comprehensive income**  
**For the year ended 30 June 2015**



	<b>Note</b>	<b>Consolidated 2015 \$'000</b>	<b>2014 \$'000</b>
<b>Revenue</b>	4	233,696	201,249
Share of profits of associates accounted for using the equity method	5	563	189
Other income	6	1,067	302
<b>Expenses</b>			
Fertility specialists, consumables and associated costs		(63,718)	(53,854)
Employee benefits expense		(75,996)	(61,395)
Depreciation and amortisation expense	7	(9,994)	(8,192)
Occupancy expense		(13,657)	(11,376)
Advertising and marketing		(3,683)	(2,797)
Practice equipment expenses		(1,906)	(1,355)
Professional and consulting fees		(2,603)	(1,542)
Other expenses		(12,188)	(9,668)
Finance costs	7	(9,106)	(7,719)
<b>Profit before income tax expense</b>		42,475	43,842
Income tax expense	8	(12,034)	(12,885)
<b>Profit after income tax expense for the year</b>		30,441	30,957
<b>Other comprehensive income</b>			
<i>Items that may be reclassified subsequently to profit or loss</i>			
Net change in the fair value of cash flow hedges taken to equity, net of tax	28	(380)	(96)
Foreign currency translation	28	125	(400)
Other comprehensive income for the year, net of tax		(255)	(496)
<b>Total comprehensive income for the year</b>		<u>30,186</u>	<u>30,461</u>
Profit for the year is attributable to:			
Non-controlling interest		1,007	72
Owners of Virtus Health Limited	29	29,434	30,885
		<u>30,441</u>	<u>30,957</u>
Total comprehensive income for the year is attributable to:			
Non-controlling interest		1,007	72
Owners of Virtus Health Limited		29,179	30,389
		<u>30,186</u>	<u>30,461</u>
		<b>Cents</b>	<b>Cents</b>
Basic earnings per share	46	36.86	38.80
Diluted earnings per share	46	36.54	38.48

*The above statement of comprehensive income should be read in conjunction with the accompanying notes*

**Virtus Health Limited**  
**Statement of financial position**  
**As at 30 June 2015**



	<b>Note</b>	<b>Consolidated 2015 \$'000</b>	<b>2014 \$'000</b>
<b>Assets</b>			
<b>Current assets</b>			
Cash and cash equivalents	9	18,371	21,498
Trade and other receivables	10	13,647	12,478
Inventories	11	278	166
Other	12	1,508	1,371
Total current assets		<u>33,804</u>	<u>35,513</u>
<b>Non-current assets</b>			
Investments accounted for using the equity method	13	1,489	1,489
Property, plant and equipment	14	30,822	28,207
Intangibles	15	390,763	356,077
Deferred tax	16	8,064	8,154
Other	17	304	341
Total non-current assets		<u>431,442</u>	<u>394,268</u>
<b>Total assets</b>		<u>465,246</u>	<u>429,781</u>
<b>Liabilities</b>			
<b>Current liabilities</b>			
Trade and other payables	18	23,171	23,516
Borrowings	19	50	62
Income tax	20	4,256	4,507
Provisions	21	2,908	2,418
Other	22	5,390	3,634
Total current liabilities		<u>35,775</u>	<u>34,137</u>
<b>Non-current liabilities</b>			
Borrowings	23	152,246	139,416
Derivative financial instruments	24	676	137
Provisions	25	5,523	4,663
Other financial liabilities	26	24,705	11,802
Total non-current liabilities		<u>183,150</u>	<u>156,018</u>
<b>Total liabilities</b>		<u>218,925</u>	<u>190,155</u>
<b>Net assets</b>		<u>246,321</u>	<u>239,626</u>
<b>Equity</b>			
Issued capital	27	238,429	237,135
Reserves	28	(12,989)	(1,610)
Retained profits/(accumulated losses)	29	1,995	(6,139)
Equity attributable to the owners of Virtus Health Limited		<u>227,435</u>	<u>229,386</u>
Non-controlling interest	30	18,886	10,240
<b>Total equity</b>		<u>246,321</u>	<u>239,626</u>

*The above statement of financial position should be read in conjunction with the accompanying notes*



**Virtus Health Limited**  
**Statement of changes in equity**  
**For the year ended 30 June 2015**



<b>Consolidated</b>	<b>Issued capital \$'000</b>	<b>Reserves \$'000</b>	<b>Retained profits \$'000</b>	<b>Non-controlling interest \$'000</b>	<b>Total equity \$'000</b>
Balance at 1 July 2013	231,981	10,186	(27,578)	-	214,589
Profit after income tax expense for the year	-	-	30,885	72	30,957
Other comprehensive income for the year, net of tax	-	(496)	-	-	(496)
Total comprehensive income for the year	-	(496)	30,885	72	30,461
<i>Transactions with owners in their capacity as owners:</i>					
Contributions of equity, net of transaction costs (note 27)	1,057	-	-	-	1,057
Put option business combination reserve	-	(11,756)	-	-	(11,756)
Tax benefit now determined relating to a portion of options adjustments payments made in June 2013	4,097	-	-	-	4,097
Non-controlling interest on acquisition of subsidiary	-	-	-	10,168	10,168
Share-based payments	-	456	-	-	456
Dividends paid (note 31)	-	-	(9,446)	-	(9,446)
Balance at 30 June 2014	<u>237,135</u>	<u>(1,610)</u>	<u>(6,139)</u>	<u>10,240</u>	<u>239,626</u>

<b>Consolidated</b>	<b>Issued capital \$'000</b>	<b>Reserves \$'000</b>	<b>Retained profits \$'000</b>	<b>Non-controlling interest \$'000</b>	<b>Total equity \$'000</b>
Balance at 1 July 2014	237,135	(1,610)	(6,139)	10,240	239,626
Profit after income tax expense for the year	-	-	29,434	1,007	30,441
Other comprehensive income for the year, net of tax	-	(255)	-	-	(255)
Total comprehensive income for the year	-	(255)	29,434	1,007	30,186
<i>Transactions with owners in their capacity as owners:</i>					
Contributions of equity, net of transaction costs (note 27)	1,294	-	-	-	1,294
Non-controlling interest on acquisition of subsidiary	-	-	-	6,454	6,454
Issue of shares by subsidiary to non-controlling interest	-	-	-	1,787	1,787
Dividends payable by subsidiary to non-controlling interest	-	-	-	(465)	(465)
Non-controlling interest share of reserves	-	-	-	(137)	(137)
Put option business combination reserve	-	(12,069)	-	-	(12,069)
Share-based payments	-	945	-	-	945
Dividends paid (note 31)	-	-	(21,300)	-	(21,300)
Balance at 30 June 2015	<u>238,429</u>	<u>(12,989)</u>	<u>1,995</u>	<u>18,886</u>	<u>246,321</u>

*The above statement of changes in equity should be read in conjunction with the accompanying notes*

		<b>Consolidated</b>	
	<b>Note</b>	<b>2015 \$'000</b>	<b>2014 \$'000</b>
<b>Cash flows from operating activities</b>			
Receipts from customers (inclusive of GST)		233,070	201,699
Payments to suppliers (inclusive of GST)		(173,366)	(137,689)
		59,704	64,010
Other revenue		367	302
Interest and other finance costs paid		(7,228)	(6,694)
Income taxes paid		(12,255)	(5,077)
Net cash from operating activities	45	40,588	52,541
<b>Cash flows from investing activities</b>			
Payments for acquisition of subsidiaries and businesses, net of cash acquired		(25,180)	(22,362)
Payments for property, plant and equipment and intangibles		(12,336)	(8,007)
Proceeds from disposal of property, plant and equipment		47	-
Interest received		220	349
Associate distributions received		250	50
Net cash used in investing activities		(36,999)	(29,970)
<b>Cash flows from financing activities</b>			
Proceeds from issue of shares		994	1,057
Proceeds from issue of shares to non-controlling interest		1,787	-
Payment of dividends		(21,300)	(9,446)
Dividend paid to non-controlling interest in subsidiaries		(150)	-
Proceeds from borrowings		13,000	8,000
Repayment of borrowings		-	(13,000)
Payment of fees in relation to refinancing		(1,038)	-
Payment for finance lease facility		(62)	(138)
Net cash used in financing activities		(6,769)	(13,527)
Net increase/(decrease) in cash and cash equivalents		(3,180)	9,044
Cash and cash equivalents at the beginning of the financial year		21,498	12,485
Effects of exchange rate changes on cash and cash equivalents		53	(31)
Cash and cash equivalents at the end of the financial year	9	18,371	21,498

*The above statement of cash flows should be read in conjunction with the accompanying notes*

## Note 1. Significant accounting policies

The principal accounting policies adopted in the preparation of the financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

### **New, revised or amending Accounting Standards and Interpretations adopted**

The consolidated entity has adopted all of the new, revised or amending Accounting Standards and Interpretations issued by the Australian Accounting Standards Board ('AASB') that are mandatory for the current reporting period.

Any new, revised or amending Accounting Standards or Interpretations that are not yet mandatory have not been early adopted.

The adoption of these Accounting Standards and Interpretations did not have any significant impact on the financial performance or position of the consolidated entity.

### **Basis of preparation**

These general purpose financial statements have been prepared in accordance with Australian Accounting Standards and Interpretations issued by the Australian Accounting Standards Board ('AASB') and the Corporations Act 2001, as appropriate for for-profit oriented entities. These financial statements also comply with International Financial Reporting Standards as issued by the International Accounting Standards Board ('IASB').

#### *Historical cost convention*

The financial statements have been prepared under the historical cost convention, except for, where applicable, the revaluation of available-for-sale financial assets, financial assets and liabilities at fair value through profit or loss, investment properties and derivative financial instruments.

#### *Critical accounting estimates*

The preparation of the financial statements requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the consolidated entity's accounting policies. The areas involving a higher degree of judgement or complexity, or areas where assumptions and estimates are significant to the financial statements, are disclosed in note 2.

### **Parent entity information**

In accordance with the Corporations Act 2001, these financial statements present the results of the consolidated entity only. Supplementary information about the parent entity is disclosed in note 39.

### **Principles of consolidation**

The consolidated financial statements incorporate the assets and liabilities of all subsidiaries of Virtus Health Limited ('company' or 'parent entity') as at 30 June 2015 and the results of all subsidiaries for the year then ended. Virtus Health Limited and its subsidiaries together are referred to in these financial statements as the 'consolidated entity'.

Subsidiaries are all those entities over which the consolidated entity has control. The consolidated entity controls an entity when the consolidated entity is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power to direct the activities of the entity. Subsidiaries are fully consolidated from the date on which control is transferred to the consolidated entity. They are de-consolidated from the date that control ceases.

Intercompany transactions, balances and unrealised gains on transactions between entities in the consolidated entity are eliminated. Unrealised losses are also eliminated unless the transaction provides evidence of the impairment of the asset transferred. Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the policies adopted by the consolidated entity.

The acquisition of subsidiaries is accounted for using the acquisition method of accounting. A change in ownership interest, without the loss of control, is accounted for as an equity transaction, where the difference between the consideration transferred and the book value of the share of the non-controlling interest acquired is recognised directly in equity attributable to the parent.

Non-controlling interest in the results and equity of subsidiaries are shown separately in the statement of comprehensive income, statement of financial position and statement of changes in equity of the consolidated entity. Losses incurred by the consolidated entity are attributed to the non-controlling interest in full, even if that results in a deficit balance.

## **Note 1. Significant accounting policies (continued)**

Where the consolidated entity loses control over a subsidiary, it derecognises the assets including goodwill, liabilities and non-controlling interest in the subsidiary together with any cumulative translation differences recognised in equity. The consolidated entity recognises the fair value of the consideration received and the fair value of any investment retained together with any gain or loss in profit or loss.

### **Operating segments**

Operating segments are presented using the 'management approach', where the information presented is on the same basis as the internal reports provided to the Chief Operating Decision Makers ('CODM'). The CODM is responsible for the allocation of resources to operating segments and assessing their performance.

### **Foreign currency translation**

The financial statements are presented in Australian dollars, which is Virtus Health Limited's functional and presentation currency.

#### *Foreign currency transactions*

Foreign currency transactions are translated into Australian dollars using the exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at financial year-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in profit or loss.

#### *Foreign operations*

The assets and liabilities of foreign operations are translated into Australian dollars using the exchange rates at the reporting date. The revenues and expenses of foreign operations are translated into Australian dollars using the average exchange rates, which approximate the rates at the dates of the transactions, for the period. All resulting foreign exchange differences are recognised in other comprehensive income through the foreign currency reserve in equity.

The foreign currency reserve is recognised in profit or loss when the foreign operation or net investment is disposed of.

### **Revenue recognition**

Revenue is recognised when it is probable that the economic benefit will flow to the consolidated entity and the revenue can be reliably measured. Revenue is measured at the fair value of the consideration received or receivable.

#### *Rendering of services*

Revenue from the rendering of services is recognised upon the delivery of the service to a patient or customer. Revenue is recognised on completion of a medical procedure, on supply of drugs, or on completion of an analytical test. If payments received from patients exceed the revenue recognised the difference is disclosed as deferred revenue.

#### *Deferred revenue*

Fees for fertility treatment cycles paid in advance are recognised as deferred revenue until the service has been provided whereupon the fees are recognised as revenue.

#### *Interest*

Interest revenue is recognised as interest accrues using the effective interest method. This is a method of calculating the amortised cost of a financial asset and allocating the interest income over the relevant period using the effective interest rate, which is the rate that exactly discounts estimated future cash receipts through the expected life of the financial asset to the net carrying amount of the financial asset.

#### *Rent*

Rent revenue from investment properties is recognised on a straight-line basis over the lease term. Lease incentives granted are recognised as part of the rental revenue. Contingent rentals are recognised as income in the period when earned.

#### *Other revenue*

Other revenue is recognised when it is received or when the right to receive payment is established.

## **Note 1. Significant accounting policies (continued)**

### **Income tax**

The income tax expense or benefit for the period is the tax payable on that period's taxable income based on the applicable income tax rate for each jurisdiction, adjusted by the changes in deferred tax assets and liabilities attributable to temporary differences, unused tax losses and the adjustment recognised for prior periods, where applicable.

Deferred tax assets and liabilities are recognised for temporary differences at the tax rates expected to be applied when the assets are recovered or liabilities are settled, based on those tax rates that are enacted or substantively enacted, except for:

- When the deferred income tax asset or liability arises from the initial recognition of goodwill or an asset or liability in a transaction that is not a business combination and that, at the time of the transaction, affects neither the accounting nor taxable profits; or
- When the taxable temporary difference is associated with interests in subsidiaries, associates or joint ventures, and the timing of the reversal can be controlled and it is probable that the temporary difference will not reverse in the foreseeable future.

Deferred tax assets are recognised for deductible temporary differences and unused tax losses only if it is probable that future taxable amounts will be available to utilise those temporary differences and losses.

The carrying amount of recognised and unrecognised deferred tax assets are reviewed at each reporting date. Deferred tax assets recognised are reduced to the extent that it is no longer probable that future taxable profits will be available for the carrying amount to be recovered. Previously unrecognised deferred tax assets are recognised to the extent that it is probable that there are future taxable profits available to recover the asset.

Deferred tax assets and liabilities are offset only where there is a legally enforceable right to offset current tax assets against current tax liabilities and deferred tax assets against deferred tax liabilities; and they relate to the same taxable authority on either the same taxable entity or different taxable entities which intend to settle simultaneously.

### **Current and non-current classification**

Assets and liabilities are presented in the statement of financial position based on current and non-current classification.

An asset is classified as current when: it is either expected to be realised or intended to be sold or consumed in normal operating cycle; it is held primarily for the purpose of trading; it is expected to be realised within 12 months after the reporting period; or the asset is cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least 12 months after the reporting period. All other assets are classified as non-current.

A liability is classified as current when: it is either expected to be settled in normal operating cycle; it is held primarily for the purpose of trading; it is due to be settled within 12 months after the reporting period; or there is no unconditional right to defer the settlement of the liability for at least 12 months after the reporting period. All other liabilities are classified as non-current.

Deferred tax assets and liabilities are always classified as non-current.

### **Cash and cash equivalents**

Cash and cash equivalents includes cash on hand, deposits held at call with financial institutions, other short-term, highly liquid investments with original maturities of three months or less that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value.

### **Trade and other receivables**

Trade receivables are initially recognised at fair value and subsequently measured at amortised cost using the effective interest method, less any provision for impairment. Trade receivables are generally due for settlement within 30 days.

## **Note 1. Significant accounting policies (continued)**

Collectability of trade receivables is reviewed on an ongoing basis. Debts which are known to be uncollectable are written off by reducing the carrying amount directly. A provision for impairment of trade receivables is raised when there is objective evidence that the consolidated entity will not be able to collect all amounts due according to the original terms of the receivables. Significant financial difficulties of the debtor, probability that the debtor will enter bankruptcy or financial reorganisation and default or delinquency in payments (more than 60 days overdue) are considered indicators that the trade receivable may be impaired. The amount of the impairment allowance is the difference between the asset's carrying amount and the present value of estimated future cash flows, discounted at the original effective interest rate. Cash flows relating to short-term receivables are not discounted if the effect of discounting is immaterial.

Other receivables are recognised at amortised cost, less any provision for impairment.

### **Inventories**

Stock on hand consists of medical supplies used in the diagnostic fertility procedures performed in the consolidated entity's fertility clinics. Stock on hand is stated at the lower of cost and net realisable value. Cost comprises purchase and delivery costs, net of rebates and discounts received or receivable.

Net realisable value is the estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale.

### **Derivative financial instruments**

Derivatives are initially recognised at fair value on the date a derivative contract is entered into and are subsequently remeasured to their fair value at each reporting date. The accounting for subsequent changes in fair value depends on whether the derivative is designated as a hedging instrument, and if so, the nature of the item being hedged.

Derivatives are classified as current or non-current depending on the expected period of realisation.

#### *Cash flow hedges*

Cash flow hedges are used to cover the consolidated entity's exposure to variability in cash flows that is attributable to a particular risk associated with a recognised asset or liability or a firm commitment which could affect profit or loss. The effective portion of the gain or loss on the hedging instrument is recognised directly in equity, whilst the ineffective portion is recognised in profit or loss. Amounts taken to equity are transferred out of equity and included in the measurement of the hedged transaction when the forecast transaction occurs.

Cash flow hedges are tested for effectiveness on a regular basis both retrospectively and prospectively to ensure that each hedge is highly effective and continues to be designated as a cash flow hedge. If the forecast transaction is no longer expected to occur, the amounts recognised in equity are transferred to profit or loss.

If the hedging instrument is sold, terminated, expires, exercised without replacement or rollover, or if the hedge becomes ineffective and is no longer a designated hedge, the amounts previously recognised in equity remain in equity until the forecast transaction occurs.

### **Associates**

Associates are entities over which the consolidated entity has significant influence but not control or joint control. Investments in associates are accounted for using the equity method. Under the equity method, the share of the profits or losses of the associate is recognised in profit or loss and the share of the movements in equity is recognised in other comprehensive income. Investments in associates are carried in the statement of financial position at cost plus post-acquisition changes in the consolidated entity's share of net assets of the associate. Goodwill relating to the associate is included in the carrying amount of the investment and is neither amortised nor individually tested for impairment. Dividends received or receivable from associates reduce the carrying amount of the investment.

When the consolidated entity's share of losses in an associate equals or exceeds its interest in the associate, including any unsecured long-term receivables, the consolidated entity does not recognise further losses, unless it has incurred obligations or made payments on behalf of the associate.

The consolidated entity discontinues the use of the equity method upon the loss of significant influence over the associate and recognises any retained investment at its fair value. Any difference between the associate's carrying amount, fair value of the retained investment and proceeds from disposal is recognised in profit or loss.



## Note 1. Significant accounting policies (continued)

### Property, plant and equipment

Plant and equipment is stated at historical cost less accumulated depreciation and impairment. Historical cost includes expenditure that is directly attributable to the acquisition of the items.

Depreciation is calculated on a straight-line basis to write off the net cost of each item of property, plant and equipment over their expected useful lives as follows:

Leasehold improvements	Over the life of the lease
Furniture and fittings	2 to 10 years
Office equipment	2 to 5 years
Medical equipment	2 to 5 years

The residual values, useful lives and depreciation methods are reviewed, and adjusted if appropriate, at each reporting date.

Leasehold improvements and plant and equipment under lease are depreciated over the unexpired period of the lease or the estimated useful life of the assets, whichever is shorter.

An item of property, plant and equipment is derecognised upon disposal or when there is no future economic benefit to the consolidated entity.

### Leases

The determination of whether an arrangement is or contains a lease is based on the substance of the arrangement and requires an assessment of whether the fulfilment of the arrangement is dependent on the use of a specific asset or assets and the arrangement conveys a right to use the asset.

A distinction is made between finance leases, which effectively transfer from the lessor to the lessee substantially all the risks and benefits incidental to the ownership of leased assets, and operating leases, under which the lessor effectively retains substantially all such risks and benefits.

Finance leases are capitalised. A lease asset and liability are established at the fair value of the leased assets, or if lower, the present value of minimum lease payments. Lease payments are allocated between the principal component of the lease liability and the finance costs, so as to achieve a constant rate of interest on the remaining balance of the liability.

Leased assets acquired under a finance lease are depreciated over the asset's useful life or over the shorter of the asset's useful life and the lease term if there is no reasonable certainty that the consolidated entity will obtain ownership at the end of the lease term.

Operating lease payments, net of any incentives received from the lessor, are charged to profit or loss on a straight-line basis over the term of the lease.

### Intangible assets

Intangible assets acquired as part of a business combination, other than goodwill, are initially measured at their fair value at the date of the acquisition. Intangible assets acquired separately are initially recognised at cost. Indefinite life intangible assets are not amortised and are subsequently measured at cost less any impairment. Finite life intangible assets are subsequently measured at cost less amortisation and any impairment. The gains or losses recognised in profit or loss arising from the derecognition of intangible assets are measured as the difference between net disposal proceeds and the carrying amount of the intangible asset. The method and useful lives of finite life intangible assets are reviewed annually. Changes in the expected pattern of consumption or useful life are accounted for prospectively by changing the amortisation method or period.

### Goodwill

Goodwill arises on the acquisition of a business. Goodwill is not amortised. Instead, goodwill is tested six monthly for impairment, or more frequently if events or changes in circumstances indicate that it might be impaired, and is carried at cost less accumulated impairment losses. Impairment losses on goodwill are taken to profit or loss and are not subsequently reversed.

## Note 1. Significant accounting policies (continued)

### *Software*

Significant costs associated with software are deferred and amortised on a straight-line basis over the period of their expected benefit, being their finite life of 3 to 5 years.

### *Brand names*

Brand names are amortised on a straight-line basis over the period of their expected benefit, being their finite life of 10 years.

### **Impairment of non-financial assets**

Goodwill and other intangible assets that have an indefinite useful life are not subject to amortisation and are tested every six months for impairment, or more frequently if events or changes in circumstances indicate that they might be impaired. Other non-financial assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognised for the amount by which the asset's carrying amount exceeds its recoverable amount.

Recoverable amount is the higher of an asset's fair value less costs of disposal and value-in-use. The value-in-use is the present value of the estimated future cash flows relating to the asset using a pre-tax discount rate specific to the asset or cash-generating unit to which the asset belongs. Assets that do not have independent cash flows are grouped together to form a cash-generating unit.

### **Trade and other payables**

These amounts represent liabilities for goods and services provided to the consolidated entity prior to the end of the financial year and which are unpaid. Due to their short-term nature they are measured at amortised cost and are not discounted. The amounts are unsecured and are usually paid within 30 days of recognition.

### **Borrowings**

Loans and borrowings are initially recognised at the fair value of the consideration received, net of transaction costs. They are subsequently measured at amortised cost using the effective interest method.

Where there is an unconditional right to defer settlement of the liability for at least 12 months after the reporting date, the loans or borrowings are classified as non-current.

### **Finance costs**

Finance costs attributable to qualifying assets are capitalised as part of the asset. All other finance costs are expensed in the period in which they are incurred.

### **Provisions**

Provisions are recognised when the consolidated entity has a present (legal or constructive) obligation as a result of a past event, it is probable the consolidated entity will be required to settle the obligation, and a reliable estimate can be made of the amount of the obligation. The amount recognised as a provision is the best estimate of the consideration required to settle the present obligation at the reporting date, taking into account the risks and uncertainties surrounding the obligation. If the time value of money is material, provisions are discounted using a current pre-tax rate specific to the liability. The increase in the provision resulting from the passage of time is recognised as a finance cost.

### **Employee benefits**

#### *Short-term employee benefits*

Liabilities for wages and salaries, including non-monetary benefits, annual leave and long service leave where there is no unconditional right to defer settlement of the liability are recognised in current liabilities in respect of employees' services up to the reporting date and are measured at the amounts expected to be paid when the liabilities are settled.

#### *Other long-term employee benefits*

The liability for annual leave and long service leave not expected to be settled within 12 months of the reporting date are measured as the present value of expected future payments to be made in respect of services provided by employees up to the reporting date using the projected unit credit method. Consideration is given to expected future wage and salary levels, experience of employee departures and periods of service. Expected future payments are discounted using market yields at the reporting date on corporate bonds with terms to maturity and currency that match, as closely as possible, the estimated future cash outflows.



## Note 1. Significant accounting policies (continued)

### *Defined contribution superannuation expense*

Contributions to defined contribution superannuation plans are expensed in the period in which they are incurred.

### *Share-based payments*

Equity-settled share-based compensation benefits are provided to employees.

Equity-settled transactions are awards of shares, or options over shares, that are provided to employees in exchange for the rendering of services.

The cost of equity-settled transactions are measured at fair value on grant date. Fair value is independently determined using option pricing models that takes into account the exercise price, the term of the option, the impact of dilution, the share price at grant date and expected price volatility of the underlying share, the expected dividend yield and the risk free interest rate for the term of the option, together with non-vesting conditions that do not determine whether the consolidated entity receives the services that entitle the employees to receive payment. No account is taken of any other vesting conditions.

The cost of equity-settled transactions are recognised as an expense with a corresponding increase in equity over the vesting period. The cumulative charge to profit or loss is calculated based on the grant date fair value of the award, the best estimate of the number of awards that are likely to vest and the expired portion of the vesting period. The amount recognised in profit or loss for the period is the cumulative amount calculated at each reporting date less amounts already recognised in previous periods.

Market conditions are taken into consideration in determining fair value. Therefore any awards subject to market conditions are considered to vest irrespective of whether or not that market condition has been met, provided all other conditions are satisfied.

If equity-settled awards are modified, as a minimum an expense is recognised as if the modification has not been made. An additional expense is recognised, over the remaining vesting period, for any modification that increases the total fair value of the share-based compensation benefit as at the date of modification.

If the non-vesting condition is within the control of the consolidated entity or employee, the failure to satisfy the condition is treated as a cancellation. If the condition is not within the control of the consolidated entity or employee and is not satisfied during the vesting period, any remaining expense for the award is recognised over the remaining vesting period, unless the award is forfeited.

If equity-settled awards are cancelled, it is treated as if it has vested on the date of cancellation, and any remaining expense is recognised immediately. If a new replacement award is substituted for the cancelled award, the cancelled and new award is treated as if they were a modification.

### *Profit sharing and bonus plans*

The consolidated entity recognises a liability and an expense for bonuses and profit sharing based on a formula that takes into consideration the profit attributable to the company's shareholders after certain adjustments. The consolidated entity recognises a provision where contractually obliged or where there is a past practice that has created a constructive obligation.

## **Fair value measurement**

When an asset or liability, financial or non-financial, is measured at fair value for recognition or disclosure purposes, the fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date; and assumes that the transaction will take place either: in the principal market; or in the absence of a principal market, in the most advantageous market.

Fair value is measured using the assumptions that market participants would use when pricing the asset or liability, assuming they act in their economic best interests. For non-financial assets, the fair value measurement is based on its highest and best use. Valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, are used, maximising the use of relevant observable inputs and minimising the use of unobservable inputs.

### **Note 1. Significant accounting policies (continued)**

Assets and liabilities measured at fair value are classified, into three levels, using a fair value hierarchy that reflects the significance of the inputs used in making the measurements. Classifications are reviewed at each reporting date and transfers between levels are determined based on a reassessment of the lowest level of input that is significant to the fair value measurement.

For recurring and non-recurring fair value measurements, external valuers may be used when internal expertise is either not available or when the valuation is deemed to be significant. External valuers are selected based on market knowledge and reputation. Where there is a significant change in fair value of an asset or liability from one period to another, an analysis is undertaken, which includes a verification of the major inputs applied in the latest valuation and a comparison, where applicable, with external sources of data.

#### **Issued capital**

Ordinary shares are classified as equity.

Incremental costs directly attributable to the issue of new shares or options are shown in equity as a deduction, net of tax, from the proceeds.

#### **Dividends**

Dividends are recognised when declared during the financial year and no longer at the discretion of the company.

#### **Business combinations**

The acquisition method of accounting is used to account for business combinations regardless of whether equity instruments or other assets are acquired.

The consideration transferred is the sum of the acquisition-date fair values of the assets transferred, equity instruments issued or liabilities incurred by the acquirer to former owners of the acquiree and the amount of any non-controlling interest in the acquiree. For each business combination, the non-controlling interest in the acquiree is measured at either fair value or at the proportionate share of the acquiree's identifiable net assets. All acquisition costs are expensed as incurred to profit or loss.

On the acquisition of a business, the consolidated entity assesses the financial assets acquired and liabilities assumed for appropriate classification and designation in accordance with the contractual terms, economic conditions, the consolidated entity's operating or accounting policies and other pertinent conditions in existence at the acquisition-date.

Where the business combination is achieved in stages, the consolidated entity remeasures its previously held equity interest in the acquiree at the acquisition-date fair value and the difference between the fair value and the previous carrying amount is recognised in profit or loss.

Contingent consideration to be transferred by the acquirer is recognised at the acquisition-date fair value. Subsequent changes in the fair value of the contingent consideration classified as an asset or liability is recognised in profit or loss. Contingent consideration classified as equity is not remeasured and its subsequent settlement is accounted for within equity.

The difference between the acquisition-date fair value of assets acquired, liabilities assumed and any non-controlling interest in the acquiree and the fair value of the consideration transferred and the fair value of any pre-existing investment in the acquiree is recognised as goodwill. If the consideration transferred and the pre-existing fair value is less than the fair value of the identifiable net assets acquired, being a bargain purchase to the acquirer, the difference is recognised as a gain directly in profit or loss by the acquirer on the acquisition-date, but only after a reassessment of the identification and measurement of the net assets acquired, the non-controlling interest in the acquiree, if any, the consideration transferred and the acquirer's previously held equity interest in the acquirer.

Business combinations are initially accounted for on a provisional basis. The acquirer retrospectively adjusts the provisional amounts recognised and also recognises additional assets or liabilities during the measurement period, based on new information obtained about the facts and circumstances that existed at the acquisition-date. The measurement period ends on either the earlier of (i) 12 months from the date of the acquisition or (ii) when the acquirer receives all the information possible to determine fair value.

## Note 1. Significant accounting policies (continued)

### Earnings per share

#### *Basic earnings per share*

Basic earnings per share is calculated by dividing the profit attributable to the owners of Virtus Health Limited, excluding any costs of servicing equity other than ordinary shares, by the weighted average number of ordinary shares outstanding during the financial year, adjusted for bonus elements in ordinary shares issued during the financial year.

#### *Diluted earnings per share*

Diluted earnings per share adjusts the figures used in the determination of basic earnings per share to take into account the after income tax effect of interest and other financing costs associated with dilutive potential ordinary shares and the weighted average number of shares assumed to have been issued for no consideration in relation to dilutive potential ordinary shares.

### Goods and Services Tax ('GST') and other similar taxes

Revenues, expenses and assets are recognised net of the amount of associated GST, unless the GST incurred is not recoverable from the tax authority. In this case it is recognised as part of the cost of the acquisition of the asset or as part of the expense.

Receivables and payables are stated inclusive of the amount of GST receivable or payable. The net amount of GST recoverable from, or payable to, the tax authority is included in other receivables or other payables in the statement of financial position.

Cash flows are presented on a gross basis. The GST components of cash flows arising from investing or financing activities which are recoverable from, or payable to the tax authority, are presented as operating cash flows.

Commitments and contingencies are disclosed net of the amount of GST recoverable from, or payable to, the tax authority.

### Rounding of amounts

The company is of a kind referred to in Class Order 98/100, issued by the Australian Securities and Investments Commission, relating to 'rounding-off'. Amounts in this report have been rounded off in accordance with that Class Order to the nearest thousand dollars, or in certain cases, the nearest dollar.

### New Accounting Standards and Interpretations not yet mandatory or early adopted

Australian Accounting Standards and Interpretations that have recently been issued or amended but are not yet mandatory, have not been early adopted by the consolidated entity for the annual reporting period ended 30 June 2015. The consolidated entity's assessment of the impact of these new or amended Accounting Standards and Interpretations, most relevant to the consolidated entity, are set out below.

#### *AASB 9 Financial Instruments*

This standard is applicable to annual reporting periods beginning on or after 1 January 2018. The standard replaces all previous versions of AASB 9 and completes the project to replace IAS 39 'Financial Instruments: Recognition and Measurement'. AASB 9 introduces new classification and measurement models for financial assets. New simpler hedge accounting requirements are intended to more closely align the accounting treatment with the risk management activities of the entity. New impairment requirements will use an 'expected credit loss' model to recognise an allowance. The consolidated entity will adopt this standard from 1 July 2018 which is not expected to have a significant impact.

#### *IFRS 15 Revenue from Contracts with Customers*

This standard is currently applicable to annual reporting periods beginning on or after 1 January 2018. The standard provides a single standard for revenue recognition. The core principle of the standard is that an entity will recognise revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The consolidated entity expects to adopt this standard from 1 July 2018 but the impact of its adoption is yet to be assessed.

Other amending accounting standards issued are not considered to have a significant impact on the financial statements of the consolidated entity as their amendments provide either clarification of existing accounting treatment or editorial amendments.

## Note 2. Critical accounting judgements, estimates and assumptions

The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the reported amounts in the financial statements. Management continually evaluates its judgements and estimates in relation to assets, liabilities, contingent liabilities, revenue and expenses. Management bases its judgements, estimates and assumptions on historical experience and on other various factors, including expectations of future events, management believes to be reasonable under the circumstances. The resulting accounting judgements and estimates will seldom equal the related actual results. The judgements, estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities (refer to the respective notes) within the next financial year are discussed below.

### *Share-based payment transactions*

The consolidated entity measures the cost of equity-settled transactions with employees by reference to the fair value of the equity instruments at the date at which they are granted. The fair value is determined by using option-pricing models taking into account the terms and conditions upon which the instruments were granted. The accounting estimates and assumptions relating to equity-settled share-based payments would have no impact on the carrying amounts of assets and liabilities within the next annual reporting period but may impact profit or loss and equity.

### *Provision for impairment of receivables*

The provision for impairment of receivables assessment requires a degree of estimation and judgement. The level of provision is assessed by taking into account the recent sales experience, the ageing of receivables, historical collection rates and specific knowledge of the individual debtors financial position.

### *Goodwill and other indefinite life intangible assets*

The consolidated entity tests six monthly, or more frequently if events or changes in circumstances indicate impairment, whether goodwill and other indefinite life intangible assets have suffered any impairment, in accordance with the accounting policy stated in note 1. The recoverable amounts of cash-generating units have been determined based on value-in-use calculations. These calculations require the use of assumptions, including estimated discount rates based on the current cost of capital and growth rates of the estimated future cash flows.

### *Impairment of non-financial assets other than goodwill and other indefinite life intangible assets*

The consolidated entity assesses impairment of non-financial assets other than goodwill and other indefinite life intangible assets at each reporting date by evaluating conditions specific to the consolidated entity and to the particular asset that may lead to impairment. If an impairment trigger exists, the recoverable amount of the asset is determined. This involves fair value less costs of disposal or value-in-use calculations, which incorporate a number of key estimates and assumptions.

### *Business combinations*

As discussed in note 1, business combinations are initially accounted for on a provisional basis. The fair value of assets acquired, liabilities and contingent liabilities assumed are initially estimated by the consolidated entity taking into consideration all available information at the reporting date. Fair value adjustments on the finalisation of the business combination accounting is retrospective, where applicable, to the period the combination occurred and may have an impact on the assets and liabilities, depreciation and amortisation reported.

The determination of the liability relating to put options linked to business combinations requires estimations to be made of the future profitability of the acquired entity and the discount rates used.

## Note 3. Operating segments

### *Identification of reportable operating segments*

AASB 8 'Operating Segments' requires operating segments to be identified on the basis of internal reports about components of the consolidated entity that are regularly reviewed by the chief operating decision maker in order to allocate resources to the segment and to assess its performance. The consolidated entity currently has five operating segments being New South Wales, Queensland, Victoria, Tasmania and International. The consolidated entity has determined that the disclosure of two segments, being an Australian aggregated healthcare services segment and an International healthcare services segment is most appropriate. Disclosure of an aggregated segment for Australia is considered appropriate due to the similar economic characteristics faced by the operating segments and the similar nature of the products and services being delivered to a similar customer base.

### Note 3. Operating segments (continued)

Following the acquisition of SIMS Clinic Limited on 30 May 2014, an international segment was created. This segment includes the Asia development costs and the set-up costs relating to the planned Singapore operations.

#### Segment revenue

Sales between segments are carried out at arm's length and are eliminated on consolidation. The revenue from external parties reported to the Board of Directors is measured in a manner consistent with that in the statement of comprehensive income.

Revenue from external customers is derived from the provision of healthcare services. A breakdown of revenue and results is provided below:

#### Segment EBITDA

Segment performance is assessed on the basis of Segment EBITDA. Segment EBITDA comprises expenses which are incurred in the normal trading activity of the segments and excludes the impact of depreciation, amortisation, interest, share-based payments and other items which are determined to be outside of the control of the respective segments. Corporate costs have been excluded from the segment EBITDA during 2015 and the comparatives have been adjusted accordingly.

#### Operating segment information

	Healthcare services Australia \$'000	Healthcare services International \$'000	Intersegment eliminations/ unallocated \$'000	Total \$'000
<b>Consolidated - 2015</b>				
<b>Revenue</b>				
Sales to external customers	205,231	27,186	-	232,417
Intersegment sales	2,420	-	(2,420)	-
Total sales revenue	207,651	27,186	(2,420)	232,417
Other revenue	1,059	-	-	1,059
Interest revenue	201	1	18	220
<b>Total revenue</b>	<b>208,911</b>	<b>27,187</b>	<b>(2,402)</b>	<b>233,696</b>
<b>Segment EBITDA</b>	<b>68,575</b>	<b>2,402</b>	<b>-</b>	<b>70,977</b>
Share based payment expense				(945)
Corporate costs				(8,007)
Foreign exchange gain				176
Transaction costs				(1,146)
Net gain on acquisition of associate				300
Depreciation and amortisation expense				(9,994)
Interest revenue				220
Interest expense				(7,235)
Interest on other financial liability - non-cash interest				(960)
Amortisation of bank facility fee				(911)
<b>Profit before income tax expense</b>				<b>42,475</b>
Income tax expense				(12,034)
<b>Profit after income tax expense</b>				<b>30,441</b>
<b>Total assets includes:</b>				
Investments in associates	1,489	-	-	1,489
Acquisition of non-current assets	28,791	15,264	3,593	47,648

**Note 3. Operating segments (continued)**

	Healthcare Services Australia \$'000	Healthcare Services International \$'000	Intersegment eliminations/ unallocated \$'000	Total \$'000
<b>Consolidated - 2014</b>				
<b>Revenue</b>				
Sales to external customers	198,484	1,535	-	200,019
Intersegment sales	4,728	-	(4,728)	-
Total sales revenue	203,212	1,535	(4,728)	200,019
Other revenue	876	5	-	881
Interest revenue	314	-	35	349
<b>Total revenue</b>	<b>204,402</b>	<b>1,540</b>	<b>(4,693)</b>	<b>201,249</b>
<b>Segment EBITDA</b>	<b>67,290</b>	<b>591</b>	<b>-</b>	<b>67,881</b>
Share based payment expense				(456)
Corporate costs				(6,742)
Foreign exchange loss				(311)
Transaction costs				(968)
Depreciation and amortisation expense				(8,192)
Interest revenue				349
Interest expense				(7,211)
Interest on other financial liability - non-cash interest				(45)
Amortisation of bank facility fee				(463)
<b>Profit before income tax expense</b>				<b>43,842</b>
Income tax expense				(12,885)
<b>Profit after income tax expense</b>				<b>30,957</b>
<i>Total assets includes:</i>				
Investments in associates	1,489	-	-	1,489
Acquisition of non-current assets	5,723	33,000	2,284	41,007

**Note 4. Revenue**

	<b>Consolidated</b>	
	<b>2015</b>	<b>2014</b>
	<b>\$'000</b>	<b>\$'000</b>
<i>Sales revenue</i>		
Rendering of services	232,417	200,019
<i>Other revenue</i>		
Interest	220	349
Rent	1,059	881
	<u>1,279</u>	<u>1,230</u>
Revenue	<u><u>233,696</u></u>	<u><u>201,249</u></u>

**Note 5. Share of profits of associates accounted for using the equity method**

	<b>Consolidated</b>	
	<b>2015</b>	<b>2014</b>
	<b>\$'000</b>	<b>\$'000</b>
Share of profits - associates	<u><u>563</u></u>	<u><u>189</u></u>

## Note 6. Other income

	Consolidated	
	2015	2014
	\$'000	\$'000
Other income	1,067	302

## Note 7. Expenses

	Consolidated	
	2015	2014
	\$'000	\$'000
Profit before income tax includes the following specific expenses:		
<i>Depreciation</i>		
Leasehold improvements	3,471	3,239
Plant and equipment under lease	48	-
Furniture and fittings	289	111
Office equipment	1,624	290
Medical equipment	2,541	2,723
Total depreciation	7,973	6,363
<i>Amortisation</i>		
Software	561	911
Brand names	1,460	918
Total amortisation	2,021	1,829
Total depreciation and amortisation	9,994	8,192
<i>Finance costs</i>		
Interest and finance charges paid/payable	7,235	7,211
Interest on other financial liability - non-cash interest	960	45
Amortisation of bank facility fees	911	463
Finance costs expensed	9,106	7,719
<i>Rental expense relating to operating leases</i>		
Minimum lease payments	10,289	8,557
<i>Superannuation expense</i>		
Defined contribution superannuation expense	4,992	4,094
<i>Research costs</i>		
Research costs	3,544	3,441
<i>Share-based payments expense</i>		
Share-based payments expense - fertility specialists	642	283
Share-based payments expense - employee benefits	303	173
Total share-based payments expense	945	456



## Note 8. Income tax expense

	<b>Consolidated</b>	
	<b>2015</b>	<b>2014</b>
	<b>\$'000</b>	<b>\$'000</b>
<i>Income tax expense</i>		
Current tax	12,675	10,947
Deferred tax - origination and reversal of temporary differences	(45)	2,308
Adjustment recognised for prior periods	(596)	(370)
	<u>12,034</u>	<u>12,885</u>
Aggregate income tax expense	<u>12,034</u>	<u>12,885</u>
Deferred tax included in income tax expense comprises:		
Decrease/(increase) in deferred tax assets (note 16)	(45)	2,308
<i>Numerical reconciliation of income tax expense and tax at the statutory rate</i>		
Profit before income tax expense	42,475	43,842
Tax at the statutory tax rate of 30%	12,743	13,153
Tax effect amounts which are not deductible/(taxable) in calculating taxable income:		
Share-based payments	284	137
Research and development	(963)	(434)
Acquisition transaction costs	344	256
Other	146	32
Tax losses not recognised	393	92
	<u>12,947</u>	<u>13,236</u>
Difference in overseas tax rates	(317)	19
Adjustment recognised for prior periods	(596)	(370)
	<u>12,034</u>	<u>12,885</u>

	<b>Consolidated</b>	
	<b>2015</b>	<b>2014</b>
	<b>\$'000</b>	<b>\$'000</b>
<i>Amounts credited directly to equity</i>		
Deferred tax assets (note 16)	(163)	(4,138)
<i>Tax losses not recognised</i>		
Unused tax losses for which no deferred tax asset has been recognised	2,806	526
Potential tax benefit at 17%	477	89

The above potential tax benefit for tax losses has not been recognised in the statement of financial position. These tax losses can be utilised in the future.

## Note 9. Current assets - cash and cash equivalents

	<b>Consolidated</b>	
	<b>2015</b>	<b>2014</b>
	<b>\$'000</b>	<b>\$'000</b>
Cash at bank and on hand	<u>18,371</u>	<u>21,498</u>



**Note 10. Current assets - trade and other receivables**

	<b>Consolidated</b>	
	<b>2015</b>	<b>2014</b>
	<b>\$'000</b>	<b>\$'000</b>
Trade receivables	12,807	11,748
Less: Provision for impairment of receivables	(1,535)	(1,104)
	<u>11,272</u>	<u>10,644</u>
Other receivables	<u>2,375</u>	<u>1,834</u>
	<u><u>13,647</u></u>	<u><u>12,478</u></u>

*Impairment of receivables*

The consolidated entity has recognised a loss of \$775,000 (2014: \$355,000) in profit or loss in respect of impairment of receivables for the year ended 30 June 2015.

The ageing of the impaired receivables provided for above is as follows:

	<b>Consolidated</b>	
	<b>2015</b>	<b>2014</b>
	<b>\$'000</b>	<b>\$'000</b>
3 to 6 months overdue	470	461
Over 6 months overdue	<u>1,065</u>	<u>643</u>
	<u><u>1,535</u></u>	<u><u>1,104</u></u>

The nominal value of the impaired receivables is \$2,004,000 (2014: \$1,565,000).

Movements in the provision for impairment of receivables are as follows:

	<b>Consolidated</b>	
	<b>2015</b>	<b>2014</b>
	<b>\$'000</b>	<b>\$'000</b>
Opening balance	1,104	1,229
Additional provisions recognised	835	510
Additions through business combinations	25	192
Receivables written off during the year as uncollectable	(369)	(672)
Unused amounts reversed	<u>(60)</u>	<u>(155)</u>
Closing balance	<u><u>1,535</u></u>	<u><u>1,104</u></u>

*Past due but not impaired*

Customers with balances past due but without provision for impairment of receivables amount to \$2,778,000 as at 30 June 2015 (\$1,537,000 as at 30 June 2014).

The consolidated entity did not consider the credit risk to be material on the aggregate balances after reviewing credit terms of customers based on recent collection practices.

The ageing of the past due but not impaired receivables are as follows:

	<b>Consolidated</b>	
	<b>2015</b>	<b>2014</b>
	<b>\$'000</b>	<b>\$'000</b>
1 to 3 months overdue	<u><u>2,778</u></u>	<u><u>1,537</u></u>

**Note 10. Current assets - trade and other receivables (continued)**

No collateral is held in relation to the above receivables.

**Note 11. Current assets - inventories**

	Consolidated	
	2015	2014
	\$'000	\$'000
Stock on hand - at cost	278	166

**Note 12. Current assets - other**

	Consolidated	
	2015	2014
	\$'000	\$'000
Prepayments	1,508	1,371

**Note 13. Non-current assets - investments accounted for using the equity method**

	Consolidated	
	2015	2014
	\$'000	\$'000
Investment in associates	1,489	1,489

Refer to note 42 for further information on interests in associates.

**Note 14. Non-current assets - property, plant and equipment**

	Consolidated	
	2015	2014
	\$'000	\$'000
Leasehold improvements - at cost	33,666	28,732
Less: Accumulated depreciation	(19,252)	(14,125)
	14,414	14,607
Plant and equipment under lease - at cost	2,689	1,990
Less: Accumulated depreciation	(2,475)	(1,990)
	214	-
Furniture and fittings - at cost	2,182	1,218
Less: Accumulated depreciation	(830)	(494)
	1,352	724
Office equipment - at cost	10,412	3,460
Less: Accumulated depreciation	(5,149)	(1,886)
	5,263	1,574
Medical equipment - at cost	23,020	21,468
Less: Accumulated depreciation	(13,441)	(10,166)
	9,579	11,302
	30,822	28,207

**Note 14. Non-current assets - property, plant and equipment (continued)**

*Reconciliations*

Reconciliations of the written down values at the beginning and end of the current and previous financial year are set out below:

<b>Consolidated</b>	Leasehold improvements \$'000	Plant and equipment under lease \$'000	Furniture and fittings \$'000	Office equipment \$'000	Medical equipment \$'000	Total \$'000
Balance at 1 July 2013	16,578	-	568	729	8,704	26,579
Additions	1,504	-	175	1,107	4,121	6,907
Additions through business combinations (note 40)	108	-	93	-	1,227	1,428
Disposals	(160)	-	-	-	(10)	(170)
Exchange differences	(1)	-	(1)	-	(17)	(19)
Transfers in/(out)	(183)	-	-	28	-	(155)
Depreciation expense	(3,239)	-	(111)	(290)	(2,723)	(6,363)
Balance at 30 June 2014	14,607	-	724	1,574	11,302	28,207
Additions	3,123	6	958	2,006	3,755	9,848
Additions through business combinations (note 40)	219	256	155	65	221	916
Disposals	(265)	-	(3)	(27)	(59)	(354)
Exchange differences	19	-	63	(2)	(13)	67
Transfers in/(out)	182	-	(256)	3,271	(3,086)	111
Depreciation expense	(3,471)	(48)	(289)	(1,624)	(2,541)	(7,973)
Balance at 30 June 2015	<u>14,414</u>	<u>214</u>	<u>1,352</u>	<u>5,263</u>	<u>9,579</u>	<u>30,822</u>

*Property, plant and equipment secured under finance leases*

Refer to note 37 for further information on property, plant and equipment secured under finance leases.

**Note 15. Non-current assets - intangibles**

	<b>Consolidated</b>	
	<b>2015</b>	<b>2014</b>
	<b>\$'000</b>	<b>\$'000</b>
Goodwill - at cost	379,168	345,988
Software - at cost	14,979	12,347
Less: Accumulated amortisation	(11,422)	(10,861)
	<u>3,557</u>	<u>1,486</u>
Brand names - at cost	14,475	13,581
Less: Accumulated amortisation	(6,437)	(4,978)
	<u>8,038</u>	<u>8,603</u>
	<u>390,763</u>	<u>356,077</u>

## Note 15. Non-current assets - intangibles (continued)

### Reconciliations

Reconciliations of the written down values at the beginning and end of the current and previous financial year are set out below:

Consolidated	Goodwill \$'000	Software \$'000	Brand names \$'000	Total \$'000
Balance at 1 July 2013	319,029	993	5,038	325,060
Additions	-	1,100	-	1,100
Additions through business combinations (note 40)	27,291	149	4,538	31,978
Exchange differences	(332)	-	(55)	(387)
Transfers in/(out)	-	155	-	155
Amortisation expense	-	(911)	(918)	(1,829)
Balance at 30 June 2014	345,988	1,486	8,603	356,077
Additions	-	2,745	-	2,745
Additions through business combinations (note 40)	33,405	7	886	34,298
Exchange differences	(225)	(9)	9	(225)
Transfers in/(out)	-	(111)	-	(111)
Amortisation expense	-	(561)	(1,460)	(2,021)
Balance at 30 June 2015	<u>379,168</u>	<u>3,557</u>	<u>8,038</u>	<u>390,763</u>

### Impairment tests for goodwill

Goodwill is allocated to the group's cash generating units ('CGUs') identified according to operating segment:

	Consolidated	
	2015 \$'000	2014 \$'000
New South Wales	114,881	114,881
Victoria	124,904	124,904
Queensland	80,689	79,244
Tasmania	21,999	-
International	36,695	26,959
	<u>379,168</u>	<u>345,988</u>

The recoverable amount of a CGU is determined based on value in use calculations. These calculations use cash flow projections based on financial budgets approved by management covering a one year period. Cash flows beyond the one year period are extrapolated using the estimated growth rates stated below. The growth rate does not exceed the long term average growth rate for the business.

### Key assumptions used for value in use calculations

#### Terminal growth rate

New South Wales - 2.5% (2014: 2.5%)

Victoria - 2.5% (2014: 2.5%)

Queensland - 2.5% (2014: 2.5%)

Tasmania - 2.5% (2014: n/a)

International - 2.5% (2014: n/a)

## Note 15. Non-current assets - intangibles (continued)

Pre-tax discount rate  
New South Wales - 10.9% (2014: 11.5%)  
Victoria - 10.9% (2014: 11.5%)  
Queensland - 10.9% (2014: 11.5%)  
Tasmania - 10.9% (2014: n/a)  
International - 10.9% (2014: n/a)

These assumptions have been used for the analysis of each CGU within the business segment. The equity rates of return and therefore discount rates reflect specific risks relating to the relevant segments. In performing the value-in-use calculations for each CGU, the consolidated entity has applied post tax discount rates to discount the forecast future attributable post-tax cash flows. The equivalent pre-tax discount rates are disclosed above.

### Impact of possible changes in assumptions

A reasonable possible change in assumptions would not cause the carrying amount of each CGU to exceed its recoverable amount.

## Note 16. Non-current assets - deferred tax

	<b>Consolidated</b>	
	<b>2015</b>	<b>2014</b>
	<b>\$'000</b>	<b>\$'000</b>
<i>Deferred tax asset comprises temporary differences attributable to:</i>		
Amounts recognised in profit or loss:		
Impairment of receivables	395	331
Property, plant and equipment	(239)	(262)
Employee benefits	2,768	2,499
Provision for lease make good	939	919
Accrued expenses	703	253
Intangible assets	(1,329)	(1,822)
Other	2,230	2,322
	<u>5,467</u>	<u>4,240</u>
Amounts recognised in equity:		
Transaction costs on share issue	755	1,415
Deductible option adjustment payments	1,639	2,458
Other	203	41
	<u>2,597</u>	<u>3,914</u>
Deferred tax assets	<u>8,064</u>	<u>8,154</u>
Amount expected to be recovered within 12 months	3,544	1,760
Amount expected to be recovered after more than 12 months	4,520	6,394
	<u>8,064</u>	<u>8,154</u>
Movements:		
Opening balance	8,154	6,877
Credited/(charged) to profit or loss (note 8)	45	(2,308)
Credited to equity (note 8)	163	4,138
Additions through business combinations (note 40)	(298)	(553)
Closing balance	<u>8,064</u>	<u>8,154</u>

**Note 17. Non-current assets - other**

	<b>Consolidated</b>	
	<b>2015</b>	<b>2014</b>
	<b>\$'000</b>	<b>\$'000</b>
Security deposits	304	341

**Note 18. Current liabilities - trade and other payables**

	<b>Consolidated</b>	
	<b>2015</b>	<b>2014</b>
	<b>\$'000</b>	<b>\$'000</b>
Trade payables	10,331	10,284
Other payables	12,840	13,232
	23,171	23,516

Refer to note 32 for further information on financial risk management.

**Note 19. Current liabilities - borrowings**

	<b>Consolidated</b>	
	<b>2015</b>	<b>2014</b>
	<b>\$'000</b>	<b>\$'000</b>
Lease liability	50	62

Refer to note 23 for further information on assets pledged as security and financing arrangements.

Refer to note 32 for further information on financial risk management.

**Note 20. Current liabilities - income tax**

	<b>Consolidated</b>	
	<b>2015</b>	<b>2014</b>
	<b>\$'000</b>	<b>\$'000</b>
Provision for income tax	4,256	4,507

**Note 21. Current liabilities - provisions**

	<b>Consolidated</b>	
	<b>2015</b>	<b>2014</b>
	<b>\$'000</b>	<b>\$'000</b>
Employee benefits - long service leave	2,908	2,418

*Amounts not expected to be settled within the next 12 months*

The current provision for long service leave includes all unconditional entitlements where employees have completed the required period of service and also those where employees are entitled to pro-rata payments in certain circumstances. The entire amount is presented as current, since the consolidated entity does not have an unconditional right to defer settlement. However, based on past experience, the consolidated entity does not expect all employees to take the full amount of accrued long service leave or require payment within the next 12 months.

## Note 21. Current liabilities - provisions (continued)

The following amounts reflect leave that is not expected to be taken within the next 12 months:

	Consolidated	
	2015	2014
	\$'000	\$'000
Long service leave obligation expected to be settled after 12 months	2,082	1,731

## Note 22. Current liabilities - other

	Consolidated	
	2015	2014
	\$'000	\$'000
Deferred revenue	5,390	3,634

## Note 23. Non-current liabilities - borrowings

	Consolidated	
	2015	2014
	\$'000	\$'000
Bank loans (net of borrowing costs)	152,148	139,281
Lease liability	98	135
	152,246	139,416

Refer to note 32 for further information on financial risk management.

### Total secured liabilities

The total secured liabilities (current and non-current) are as follows:

	Consolidated	
	2015	2014
	\$'000	\$'000
Bank loans (net of borrowing costs)	152,148	139,281
Lease liability	148	197
	152,296	139,478

### Assets pledged as security

The bank loans are secured by guarantees by all group companies and fixed and floating charges over the consolidated entity's assets. Guarantees are not provided by subsidiaries which are not based in Australia and there are no fixed or floating charges over the assets of the international subsidiaries of the consolidated entity. However the shares representing the ownership interest in the international subsidiaries are included in the charges over the consolidated entity.

The lease liabilities are effectively secured as the rights to the leased assets, recognised in the statement of financial position, revert to the lessor in the event of default.

The assets of City West Specialist Day Hospital Pty Ltd and Obstetrics & Gynaecological Imaging Australia Pty Limited are excluded from the assets pledged as security. However the units representing the 50% interest are included in the charges over the consolidated entity.

**Note 23. Non-current liabilities - borrowings (continued)**

The carrying amounts of assets pledged as security for current and non-current borrowings are:

	<b>Consolidated</b>	
	<b>2015</b>	<b>2014</b>
	<b>\$'000</b>	<b>\$'000</b>
Cash and cash equivalents	16,130	18,820
Receivables	10,835	11,052
Inventories	278	192
Other current assets	1,158	1,251
Investments	30,065	24,972
Plant and equipment	24,997	26,783
Intangible assets (excluding goodwill)	7,135	5,606
Deferred tax assets	8,304	8,140
Other financial assets	76	141
	<u>98,978</u>	<u>96,957</u>

*Financing arrangements*

Unrestricted access was available at the reporting date to the following lines of credit:

	<b>Consolidated</b>	
	<b>2015</b>	<b>2014</b>
	<b>\$'000</b>	<b>\$'000</b>
Total facilities		
Bank loans*	200,000	140,000
Working capital facilities*	10,000	10,000
	<u>210,000</u>	<u>150,000</u>
Used at the reporting date		
Bank loans (excluding capitalised borrowing costs)	153,000	140,000
Working capital facilities	3,430	3,366
	<u>156,430</u>	<u>143,366</u>
Unused at the reporting date		
Bank loans	47,000	-
Working capital facilities	6,570	6,634
	<u>53,570</u>	<u>6,634</u>

\* Credit facilities expire in September 2019

The consolidated entity has complied with the financial covenants of its borrowing liabilities during the financial year ended 30 June 2015 and 30 June 2014.

Working capital facilities utilised consist of \$3,430,000 of bank guarantees.



**Note 24. Non-current liabilities - derivative financial instruments**

	Consolidated	
	2015	2014
	\$'000	\$'000
Interest rate swap contracts - cash flow hedges	676	137

Refer to note 32 for further information on financial risk management.

Refer to note 33 for further information on fair value measurement.

**Note 25. Non-current liabilities - provisions**

	Consolidated	
	2015	2014
	\$'000	\$'000
Employee benefits - long service leave	1,761	1,599
Lease make good	3,762	3,064
	5,523	4,663

*Lease make good*

The provision represents the present value of the estimated costs to make good the premises leased by the consolidated entity at the end of the respective lease terms.

*Movements in provisions*

Movements in each class of provision during the current financial year, other than employee benefits, are set out below:

	Lease make good \$'000
<b>Consolidated - 2015</b>	
Carrying amount at the start of the year	3,064
Additional provisions recognised	640
Unwinding of discount	58
Carrying amount at the end of the year	3,762

**Note 26. Non-current liabilities - Other financial liabilities**

	Consolidated	
	2015	2014
	\$'000	\$'000
Other financial liability	24,705	11,802

Refer to note 33 for other information on financial instruments.

The other financial liability represents the fair value of the consideration to acquire the non-controlling interests in SIMS Clinic Limited and Tas IVF Pty Limited on the assumption that the put options held by the non-controlling interests are exercised.

## Note 27. Equity - issued capital

	2015 Shares	Consolidated 2014 Shares	2015 \$'000	2014 \$'000
Ordinary shares - fully paid	79,935,938	79,722,678	238,429	237,135

### Movements in ordinary share capital

Details	Date	Shares	Issue price	\$'000
Balance	1 July 2013	79,536,601		231,981
Shares issued - exercise of options	7 February 2014	50,000	\$5.68	284
Shares issued - exercise of options	11 March 2014	38,680	\$5.68	220
Shares issued - exercise of options	13 March 2014	97,397	\$5.68	553
Tax benefit now determined relating to a portion of options adjustment payments made in June 2013		-		4,097
Balance	30 June 2014	79,722,678		237,135
Shares issued - exercise of options	18 September 2014	125,000	\$5.68	710
Shares issued - acquisition of IVF Sunshine Coast Pty Limited	31 October 2014	38,260	\$7.84	300
Shares issued - exercise of options	3 March 2015	50,000	\$5.68	284
Balance	30 June 2015	79,935,938		238,429

### Ordinary shares

Ordinary shares entitle the holder to participate in dividends and the proceeds on the winding up of the company in proportion to the number of and amounts paid on the shares held. The fully paid ordinary shares have no par value and the company does not have a limited amount of authorised capital.

On a show of hands every member present at a meeting in person or by proxy shall have one vote and upon a poll each share shall have one vote.

All shares on issue are fully paid apart from 2,009,880 shares which are partly paid. The 2,009,880 shares were issued at \$4.71 per share and are unpaid up to the extent of \$2.44 per share at 30 June 2015.

### Share buy-back

There is no current on-market share buy-back.

### Capital risk management

The consolidated entity's objectives when managing capital are to safeguard its ability to continue as a going concern, so that it can provide returns for shareholders and benefits for other stakeholders and to maintain an optimum capital structure to reduce the cost of capital.

In order to maintain or adjust the capital structure, the consolidated entity may adjust the amount of dividends paid to shareholders, return capital to shareholders, issue new shares or sell assets to reduce debt.

The consolidated entity would look to raise capital when an opportunity to invest in a business or company was seen as value adding relative to the current parent entity's share price at the time of the investment.

## Note 28. Equity - reserves

	Consolidated	
	2015 \$'000	2014 \$'000
Foreign currency translation reserve	(275)	(400)
Cash flow hedges reserve	(476)	(96)
Share-based payments reserve	11,587	10,642
Put option business combination reserve	(23,825)	(11,756)
	<u>(12,989)</u>	<u>(1,610)</u>

### Foreign currency translation reserve

The reserve is used to recognise exchange differences arising from the translation of the financial statements of foreign operations to Australian dollars. It is also used to recognise gains and losses on hedges of the net investments in foreign operations.

### Cash flow hedges reserve

The reserve is used to recognise the effective portion of the gain or loss of cash flow hedge instruments that is determined to be an effective hedge.

### Share-based payments reserve

The reserve is used to recognise the value of equity benefits provided to employees and directors as part of their remuneration, and other parties as part of their compensation for services.

### Put option business combination reserve

The reserve is used to recognise the impact of the non-controlling interest put options relating to the SIMS Clinic Limited and Tas IVF Pty Limited acquisitions.

### Movements in reserves

Movements in each class of reserve during the current and previous financial year are set out below:

Consolidated	Foreign currency translation reserve \$'000	Cash flow hedges reserve \$'000	Share-based payments reserve \$'000	Put option business combination reserve \$'000	Total \$'000
Balance at 1 July 2013	-	-	10,186	-	10,186
Revaluation - net	-	(96)	-	-	(96)
Foreign currency translation	(400)	-	-	-	(400)
Option expense	-	-	456	-	456
Business combination	-	-	-	(11,756)	(11,756)
Balance at 30 June 2014	(400)	(96)	10,642	(11,756)	(1,610)
Revaluation - net	-	(380)	-	-	(380)
Foreign currency translation	125	-	-	-	125
Option expense	-	-	945	-	945
Business combinations	-	-	-	(12,069)	(12,069)
Balance at 30 June 2015	<u>(275)</u>	<u>(476)</u>	<u>11,587</u>	<u>(23,825)</u>	<u>(12,989)</u>

**Note 29. Equity - retained profits/(accumulated losses)**

	<b>Consolidated</b>	
	<b>2015</b>	<b>2014</b>
	<b>\$'000</b>	<b>\$'000</b>
Accumulated losses at the beginning of the financial year	(6,139)	(27,578)
Profit after income tax expense for the year	29,434	30,885
Dividends paid (note 31)	(21,300)	(9,446)
Retained profits/(accumulated losses) at the end of the financial year	<u>1,995</u>	<u>(6,139)</u>

**Note 30. Equity - non-controlling interest**

	<b>Consolidated</b>	
	<b>2015</b>	<b>2014</b>
	<b>\$'000</b>	<b>\$'000</b>
Issued capital	1,842	55
Reserves	15,965	10,113
Retained profits	1,079	72
	<u>18,886</u>	<u>10,240</u>

**Note 31. Equity - dividends**

*Dividends*

Dividends paid during the financial year were as follows:

	<b>Consolidated</b>	
	<b>2015</b>	<b>2014</b>
	<b>\$'000</b>	<b>\$'000</b>
Interim ordinary dividend for the year ended 30 June 2015 of 13.0 cents (2014: 12.0 cents) per fully paid share paid in April 2015	10,385	9,446
Final ordinary dividend for the year ended 30 June 2014 of 14.0 cents per fully paid ordinary share paid in October 2014	10,915	-
	<u>21,300</u>	<u>9,446</u>

A final dividend of 14.00 cents per share, fully franked, will be paid on 16 October 2015 to the shareholders on the register at 2 October 2015.

*Franking credits*

	<b>Consolidated</b>	
	<b>2015</b>	<b>2014</b>
	<b>\$'000</b>	<b>\$'000</b>
Franking credits available for subsequent financial years based on a tax rate of 30%	<u>17,245</u>	<u>13,329</u>

The above amounts represent the balance of the franking account as at the end of the financial year, adjusted for:

- franking credits that will arise from the payment of the amount of the provision for income tax at the reporting date
- franking debits that will arise from the payment of dividends recognised as a liability at the reporting date
- franking credits that will arise from the receipt of dividends recognised as receivables at the reporting date

## Note 32. Financial risk management

### Financial risk management objectives

The consolidated entity's activities expose it to a variety of financial risks: market risk (including foreign currency risk, price risk and interest rate risk), credit risk and liquidity risk. The consolidated entity's overall risk management program focuses on the unpredictability of financial markets and seeks to minimise potential adverse effects on the financial performance of the consolidated entity. The consolidated entity uses derivative financial instruments such as forward foreign exchange contracts to hedge certain risk exposures. Derivatives are exclusively used for hedging purposes, i.e. not as trading or other speculative instruments. The consolidated entity uses different methods to measure different types of risk to which it is exposed. These methods include sensitivity analysis in the case of interest rate, foreign exchange and other price risks, ageing analysis for credit risk and beta analysis in respect of investment portfolios to determine market risk.

Risk management is carried out by senior finance executives ('finance') under policies approved by the Board of Directors ('the Board'). These policies include identification and analysis of the risk exposure of the consolidated entity and appropriate procedures, controls and risk limits. Finance identifies, evaluates and hedges financial risks within the consolidated entity's operating units. Finance reports to the Board on a monthly basis.

### Market risk

#### Foreign currency risk

The group operates internationally and is exposed to foreign currency risk from various currency exposures, primarily with respect to the Euro.

Foreign exchange risk arises from future commercial transactions and recognised financial assets and financial liabilities denominated in a currency that is not the entity's functional currency. The risk is measured using sensitivity analysis and cash flow forecasting.

The carrying amount of the consolidated entity's foreign currency denominated financial assets and financial liabilities at the reporting date were not significant.

#### Price risk

The consolidated entity is exposed to changes in Commonwealth Government funding for the healthcare services the consolidated entity provides which may impact patient out-of-pocket expenses and thus demand.

#### Interest rate risk

The consolidated entity's main interest rate risk arises from long-term borrowings. Borrowings issued at variable rates expose the consolidated entity to interest rate risk. Borrowings issued at fixed rates expose the consolidated entity to fair value interest rate risk. The policy is to maintain approximately 30% of borrowings at fixed rate using interest rate swaps to achieve this when necessary.

As at the reporting date, the consolidated entity had the following variable rate borrowings and interest rate swap contracts outstanding:

	2015		2014	
	Weighted average interest rate %	Balance \$'000	Weighted average interest rate %	Balance \$'000
<b>Consolidated</b>				
Bank loans	4.10%	153,000	4.65%	140,000
Interest rate swaps (notional principal amount)	-%	(50,000)	-%	(50,000)
Net exposure to cash flow interest rate risk		<u>103,000</u>		<u>90,000</u>

During the prior year the consolidated entity entered in interest rate swap contracts hedging \$50,000,000 of its borrowings.

An analysis by remaining contractual maturities is shown in the 'liquidity and interest rate risk management' section below.

**Note 32. Financial risk management (continued)**

	Basis points change	Basis points increase		Basis points change	Basis points decrease	
		Effect on profit after tax	Effect on equity		Effect on profit after tax	Effect on equity
<b>Consolidated - 2015</b>						
Bank loans	100	<u>(721,000)</u>	<u>(721,000)</u>	(100)	<u>721,000</u>	<u>721,000</u>
	Basis points change	Basis points increase		Basis points change	Basis points decrease	
		Effect on profit after tax	Effect on equity		Effect on profit after tax	Effect on equity
<b>Consolidated - 2014</b>						
Bank loans	100	<u>(630,000)</u>	<u>(630,000)</u>	(100)	<u>630,000</u>	<u>630,000</u>

**Credit risk**

Credit risk refers to the risk that a counterparty will default on its contractual obligations resulting in financial loss to the consolidated entity. The consolidated entity has a strict code of credit, including obtaining agency credit information, confirming references and setting appropriate credit limits. The consolidated entity obtains guarantees where appropriate to mitigate credit risk. The maximum exposure to credit risk at the reporting date to recognised financial assets is the carrying amount, net of any provisions for impairment of those assets, as disclosed in the statement of financial position and notes to the financial statements. The consolidated entity does not hold any collateral.

Receivables balances and ageing analysis are monitored on an on-going basis. In order to minimise the consolidated entity's exposure to bad debts, processes are in place to send reminder notices, demands for repayment and ultimately to refer to debt collection agencies.

**Liquidity risk**

Vigilant liquidity risk management requires the consolidated entity to maintain sufficient liquid assets (mainly cash and cash equivalents) and available borrowing facilities to be able to pay debts as and when they become due and payable.

The consolidated entity manages liquidity risk by maintaining adequate cash reserves and available borrowing facilities by continuously monitoring actual and forecast cash flows and matching the maturity profiles of financial assets and liabilities.

**Financing arrangements**

Unused borrowing facilities at the reporting date:

	Consolidated	
	2015 \$'000	2014 \$'000
Bank loans*	47,000	-
Working capital facilities*	<u>6,570</u>	<u>6,634</u>
	<u>53,570</u>	<u>6,634</u>

\* Credit facilities expire in September 2019.

## Note 32. Financial risk management (continued)

### Remaining contractual maturities

The following tables detail the consolidated entity's remaining contractual maturity for its financial instrument liabilities. The tables have been drawn up based on the undiscounted cash flows of financial liabilities based on the earliest date on which the financial liabilities are required to be paid. The tables include both interest and principal cash flows disclosed as remaining contractual maturities and therefore these totals may differ from their carrying amount in the statement of financial position.

	Weighted average interest rate %	1 year or less \$'000	Between 1 and 2 years \$'000	Between 2 and 5 years \$'000	Over 5 years \$'000	Remaining contractual maturities \$'000
<b>Consolidated - 2015</b>						
<b>Non-derivatives</b>						
<i>Non-interest bearing</i>						
Trade payables	-%	10,331	-	-	-	10,331
Other payables	-%	12,840	-	-	-	12,840
<i>Interest-bearing - fixed rate</i>						
Bank loans	4.10%	6,273	6,273	167,111	-	179,657
Lease liability	7.66%	61	94	-	-	155
Other financial liability	4.10%	-	-	28,451	-	28,451
Total non-derivatives		29,505	6,367	195,562	-	231,434
<b>Derivatives</b>						
Derivative financial instruments	-%	-	-	676	-	676
Total derivatives		-	-	676	-	676
<b>Consolidated - 2014</b>						
<b>Non-derivatives</b>						
<i>Non-interest bearing</i>						
Trade payables	-%	10,284	-	-	-	10,284
Other payables	-%	13,232	-	-	-	13,232
<i>Interest-bearing - variable</i>						
Bank loans	4.65%	6,510	146,519	-	-	153,029
Lease liability	7.66%	62	122	33	-	217
Other financial liability	4.65%	-	-	6,401	7,745	14,146
Total non-derivatives		30,088	146,641	6,434	7,745	190,908
<b>Derivatives</b>						
Derivative financial instruments	-%	-	137	-	-	137
Total derivatives		-	137	-	-	137

The cash flows in the maturity analysis above are not expected to occur significantly earlier than contractually disclosed above.

### Fair value of financial instruments

Unless otherwise stated, the carrying amounts of financial instruments reflect their fair value.

### Note 33. Fair value measurement

#### Fair value hierarchy

The following tables detail the consolidated entity's assets and liabilities, measured or disclosed at fair value, using a three level hierarchy, based on the lowest level of input that is significant to the entire fair value measurement, being:

Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date

Level 2: Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly

Level 3: Unobservable inputs for the asset or liability

<b>Consolidated - 2015</b>	<b>Level 1 \$'000</b>	<b>Level 2 \$'000</b>	<b>Level 3 \$'000</b>	<b>Total \$'000</b>
<i>Liabilities</i>				
Derivative financial liabilities	-	676	-	676
Other financial liabilities	-	-	24,705	24,705
<b>Total liabilities</b>	<b>-</b>	<b>676</b>	<b>24,705</b>	<b>25,381</b>

<b>Consolidated - 2014</b>	<b>Level 1 \$'000</b>	<b>Level 2 \$'000</b>	<b>Level 3 \$'000</b>	<b>Total \$'000</b>
<i>Liabilities</i>				
Derivative financial liabilities	-	137	-	137
Other financial liabilities	-	-	11,802	11,802
<b>Total liabilities</b>	<b>-</b>	<b>137</b>	<b>11,802</b>	<b>11,939</b>

There were no transfers between levels during the financial year.

The carrying amounts of trade and other receivables and trade and other payables are assumed to approximate their fair values due to their short-term nature.

The fair value of other financial liabilities is estimated by discounting the remaining contractual maturities at the current market interest rate that is available for similar financial liabilities.

#### Valuation techniques for fair value measurements categorised within level 2 and level 3

Derivative financial instruments have been valued using quoted market rates. This valuation technique maximises the use of observable market data where it is available and relies as little as possible on entity specific estimates. Other financial liabilities have been valued using a forecast earnings model, discounted using specific borrowing rates.

#### Level 3 assets and liabilities

Movements in level 3 assets and liabilities during the current and previous financial year are set out below:

<b>Consolidated</b>	<b>Other financial liabilities \$'000</b>	<b>Total \$'000</b>
Balance at 1 July 2013	-	-
Additions	11,802	11,802
Balance at 30 June 2014	11,802	11,802
Additions	12,069	12,069
Foreign exchange impact	(126)	(126)
Interest on unwinding	960	960
<b>Balance at 30 June 2015</b>	<b>24,705</b>	<b>24,705</b>



### Note 33. Fair value measurement (continued)

The level 3 assets and liabilities unobservable inputs and sensitivity are as follows:

Description	Unobservable inputs	Sensitivity
Other financial liabilities	Discount rate	a 1% change would increase/decrease the fair value by \$615,000/(\$588,000)
	EBITDA growth rate	a 1% change would increase/decrease the fair value by \$606,000/(\$590,000)

### Note 34. Key management personnel disclosures

#### Compensation

The aggregate compensation made to directors and other members of key management personnel of the consolidated entity is set out below:

	Consolidated	
	2015	2014
	\$	\$
Short-term employee benefits	2,726,880	2,242,064
Post-employment benefits	195,512	142,475
Long-term benefits	32,617	40,538
Share-based payments	286,240	173,092
	<u>3,241,249</u>	<u>2,598,169</u>

### Note 35. Remuneration of auditors

During the financial year the following fees were paid or payable for services provided by PricewaterhouseCoopers, the auditor of the company, and its network firms:

	Consolidated	
	2015	2014
	\$	\$
<i>Audit services - PricewaterhouseCoopers</i>		
Audit or review of the financial statements	525,750	437,775
<i>Other services - PricewaterhouseCoopers</i>		
Due diligence	128,131	127,240
Tax compliance services	62,976	62,500
International tax consulting and tax advice on mergers and acquisitions	-	101,200
Non statutory audits and reviews relating to acquisitions	120,000	-
	311,107	290,940
	836,857	728,715
<i>Audit services - network firms</i>		
Audit or review of the financial statements	141,954	29,480
<i>Other services - network firms</i>		
Due diligence	-	25,373
Tax services	83,739	-
	83,739	25,373
	225,693	54,853

It is the consolidated entity's policy to utilise appropriate accounting and consulting resource for other services which may include tax advice and due diligence reporting on acquisitions, and it is the consolidated entity's policy to seek competitive tenders for such assignments as appropriate.

### Note 36. Contingent liabilities

#### Claims

The consolidated entity is currently involved in litigations which may result in future liabilities and legal fees up to an insurance excess of \$25,000. The consolidated entity has disclaimed liability and is defending the actions. It is not practical to estimate the potential effect of these claims but advice indicates that any liability that may arise in the unlikely event that the claims are successful will not be significant and will be covered by the consolidated entity's insurance policies.

#### Guarantees

Drawdowns of \$3,430,000 (2014: \$3,366,000) in the form of financial guarantees have been made against the working capital facility. Subject to the continued compliance with debt covenants, the bank facilities may be drawn at any time and have an average maturity of 4 years (2014: 2 years).

## Note 37. Commitments

	Consolidated	
	2015 \$'000	2014 \$'000
<i>Lease commitments - operating</i>		
Committed at the reporting date but not recognised as liabilities, payable:		
Within one year	8,633	6,498
One to five years	20,102	13,966
More than five years	12,297	5,827
	<u>41,032</u>	<u>26,291</u>
<i>Lease commitments - finance</i>		
Committed at the reporting date and recognised as liabilities, payable:		
Within one year	50	62
One to five years	105	155
	<u>155</u>	<u>217</u>
Total commitment	(7)	(20)
Less: Future finance charges		
	<u>148</u>	<u>197</u>
Net commitment recognised as liabilities		
Representing:		
Lease liability - current (note 19)	50	62
Lease liability - non-current (note 23)	98	135
	<u>148</u>	<u>197</u>

Operating lease commitments includes contracted amounts for various offices and medical centres under non-cancellable operating leases expiring within 2 to 8 years with, in some cases, options to extend. The leases have various escalation clauses. On renewal, the terms of the leases are renegotiated. Excess office space is sub-let to third parties also under non-cancellable operating leases. These leases have future minimum lease payments expected to be received in relation to non-cancellable sub-leases of operating leases of \$702,213 (2014: \$295,887).

Finance lease commitments includes contracted amounts for various plant and equipment with a written down value of \$nil (30 June 2014: \$nil) under finance leases expiring within 1 to 4 years. Under the terms of the leases, the consolidated entity has the option to acquire the leased assets for predetermined residual values on the expiry of the leases.

## Note 38. Related party transactions

### *Parent entity*

Virtus Health Limited is the parent entity.

### *Subsidiaries*

Interests in subsidiaries are set out in note 41.

### *Associates*

Interests in associates are set out in note 42.

### *Key management personnel*

Disclosures relating to key management personnel are set out in note 34 and the remuneration report in the directors' report.

### Note 38. Related party transactions (continued)

#### *Transactions with related parties*

The following transactions occurred with related parties:

	<b>Consolidated</b>	
	<b>2015</b>	<b>2014</b>
	<b>\$</b>	<b>\$</b>
Other revenue:		
Rental income	69,907	84,574
Other transactions:		
Provider fees (i)	2,813,773	2,468,067

(i) The following key management personnel received provider fees for IVF services delivered to patients: Lyndon Hale, Peter Illingworth, David Molloy and William Watkins (30 June 2014: Lyndon Hale, Peter Illingworth and David Molloy).

#### *Receivable from and payable to related parties*

The following balances are outstanding at the reporting date in relation to transactions with related parties:

	<b>Consolidated</b>	
	<b>2015</b>	<b>2014</b>
	<b>\$</b>	<b>\$</b>
Current receivables:		
Trade receivables from associates	1,189,450	887,965
Other receivables	6,773	5,396
Current payables:		
Other payables	268,500	159,610

#### *Terms and conditions*

All transactions were made on normal commercial terms and conditions and at market rates.

### Note 39. Parent entity information

Set out below is the supplementary information about the parent entity.

#### *Statement of comprehensive income*

	<b>Parent</b>	
	<b>2015</b>	<b>2014</b>
	<b>\$'000</b>	<b>\$'000</b>
Profit after income tax	13,349	12,759
Total comprehensive income	13,349	12,759

### Note 39. Parent entity information (continued)

#### Statement of financial position

	Parent	
	2015 \$'000	2014 \$'000
Total current assets	1,884	942
Total assets	271,072	272,634
Total current liabilities	2,579	1,306
Total liabilities	6,363	1,376
Net assets	264,709	271,258
Equity		
Issued capital	238,429	237,135
Share-based payments reserve	7,056	6,948
Retained profits	19,224	27,175
Total equity	264,709	271,258

#### Guarantees entered into by the parent entity in relation to the debts of its subsidiaries

The parent entity had no guarantees in relation to the debts of its subsidiaries as at 30 June 2015 and 30 June 2014 apart from being a party to the deed of cross guarantee as detailed in note 43.

#### Contingent liabilities

The parent entity had no contingent liabilities as at 30 June 2015 and 30 June 2014.

#### Capital commitments - Property, plant and equipment

The parent entity had no capital commitments for property, plant and equipment at as 30 June 2015 and 30 June 2014.

#### Significant accounting policies

The accounting policies of the parent entity are consistent with those of the consolidated entity, as disclosed in note 1, except for the following:

- Investments in subsidiaries are accounted for at cost, less any impairment, in the parent entity.
- Investments in associates are accounted for at cost, less any impairment, in the parent entity.
- Dividends received from subsidiaries are recognised as other income by the parent entity and its receipt may be an indicator of an impairment of the investment.

**Note 40. Business combinations**

*Human Assisted Reproduction Ireland (HARI) Limited*

On 31 December 2014 Sims Clinic Limited (a 70% subsidiary of Virtus Health Limited), formed a new company, Human Assisted Reproduction Ireland (HARI) Limited to acquire the IVF business and assets from The Governors and Guardians of the Hospital For The Relief Of Poor Lying In Women, Dublin (commonly known as the Rotunda Hospital). Total consideration transferred amounted to \$9,041,000. The values identified in relation to the acquisition of the business are provisional as at 30 June 2015.

Details of the acquisition are as follows:

	<b>Fair value \$'000</b>
Trade and other receivables	184
Plant and equipment	259
Employee benefits	(45)
Deferred revenue	(549)
	<hr/>
Net liabilities acquired	(151)
Goodwill	9,192
	<hr/>
Acquisition-date fair value of the total consideration transferred	<u>9,041</u>
	<hr/>
Representing:	
Cash paid or payable to vendor	<u>9,041</u>
	<hr/>
Acquisition costs expensed to profit or loss	<u>522</u>
	<hr/>

The acquired business contributed revenues and other income of \$3,147,000 and profit before tax of \$32,000 (including restructuring and integration costs and excluding the cost of financing the transaction) to the consolidated entity for the period from 31 December 2014 to 30 June 2015. If the acquisition had occurred on 1 July 2014, the full year contributions would have been revenues of \$6,294,000 and profit before tax of \$64,000 excluding any additional financing costs and including restructuring and integration costs. These amounts have been calculated using the consolidated entity's accounting policies and by adjusting the results of the subsidiary to reflect the additional depreciation and amortisation that would have been charged assuming the fair value adjustments to property, plant and equipment and intangible assets had applied from 1 July 2014, together with the consequential tax effects.

Goodwill is attributable to the workforce and the expected profitability of the acquired entity.

**Note 40. Business combinations (continued)**

*Tas IVF Pty Limited*

On 5 December 2014 Virtus Health Limited, acquired 70% of the issued share capital and units of Tas IVF Pty Ltd. Total consideration transferred amounted to \$15,971,000. The values identified in relation to the acquisition of the company are provisional as at 30 June 2015.

Details of the acquisition are as follows:

	<b>Fair value \$'000</b>
Cash and cash equivalents	5,756
Trade receivables	438
Plant and equipment	475
Brand names	886
Other intangible assets	7
Trade payables	(296)
Provision for income tax	(388)
Deferred tax liability	(69)
Employee benefits	(343)
Deferred revenue	(285)
Short-term debt	(5,309)
	<hr/>
Net assets acquired	872
Goodwill	21,999
	<hr/>
Acquisition-date fair value of the total consideration transferred	<u>22,871</u>
	<hr/>
Representing:	
Cash paid or payable to vendor	16,100
Working capital adjustment receivable	(129)
Non-controlling interest	6,900
	<hr/>
	<u>22,871</u>
	<hr/>
Acquisition costs expensed to profit or loss	<u>227</u>
	<hr/>
Cash used to acquire business, net of cash acquired:	
Acquisition-date fair value of the total consideration transferred	15,971
Add: Short-term debt	5,309
Less: cash and cash equivalents	(5,756)
Working capital adjustment - amount not yet settled	129
	<hr/>
Net cash used	<u>15,653</u>

The acquired business contributed revenues and other income of \$4,561,000 and profit before tax of \$1,593,000 (excluding the cost of financing the transaction) to the consolidated entity for the period from 5 December 2014 to 30 June 2015. If the acquisition had occurred on 1 July 2014, the full year contributions would have been revenues of \$7,642,000 and profit before tax of \$3,353,000 excluding any additional financing costs. These amounts have been calculated using the consolidated entity's accounting policies and by adjusting the results of the subsidiary to reflect the additional depreciation and amortisation that would have been charged assuming the fair value adjustments to property, plant and equipment and intangible assets had applied from 1 July 2014, together with the consequential tax effects.

Goodwill is attributable to the workforce and the profitability of the acquired entity.

**Note 40. Business combinations (continued)**

*IVF Sunshine Coast Pty Limited*

On 31 October 2014 Queensland Fertility Group Pty Limited, a fully owned subsidiary of Virtus Health Limited, acquired the remaining 80% of the issued share capital and units of IVF Sunshine Coast Pty Limited. Total consideration transferred amounted to \$1,340,000. The values identified in relation to the acquisition of the company are provisional as at 30 June 2015.

Details of the acquisition are as follows:

	<b>Fair value \$'000</b>
Cash and cash equivalents	135
Trade receivables	33
Income tax refund due	22
Other current assets	31
Plant and equipment	183
Deferred tax asset	45
Trade payables	(54)
Employee benefits	(12)
Other provisions	(133)
Deferred revenue	(182)
Lease liability	(173)
Net liabilities acquired	(105)
Goodwill	1,445
Acquisition-date fair value of the total consideration transferred	<u>1,340</u>
Representing:	
Cash paid or payable to vendor	750
Virtus Health Limited shares issued to vendor	300
Gain on remeasurement of previously held 20% investment to fair value	300
Working capital movement - amount not yet paid	(10)
	<u>1,340</u>
Acquisition costs expensed to profit or loss	<u>108</u>
Cash used to acquire business, net of cash acquired:	
Acquisition-date fair value of the total consideration transferred	1,040
Less: cash and cash equivalents	(135)
Less: shares issued by company as part of consideration	(300)
Working capital adjustment	10
Net cash used	<u>615</u>

The acquired business contributed revenues and other income of \$1,265,000 and profit before tax of \$137,000 (excluding the cost of financing the transaction) to the Group for the period from 1 November 2014 to 30 June 2015. If the acquisition had occurred on 1 July 2014, the full year contributions would have been revenues of \$1,785,000 and profit before tax of \$31,000 excluding any additional financing or brand amortisation costs. These amounts have been calculated using the Group's accounting policies and by adjusting the results of the subsidiary to reflect the additional depreciation and amortisation that would have been charged assuming the fair value adjustments to property, plant and equipment and intangible assets had applied from 1 July 2014, together with the consequential tax effects.

Goodwill is attributable to the workforce and the profitability of the acquired entity.



**Note 40. Business combinations (continued)**

*Acquisition of SIMS Clinic*

On 30 May 2014 Virtus Health Pty Limited, acquired 70% of the issued share capital and units of SIMS Clinic Limited.

**2015**

Since the date of acquisition there have been changes to the acquired net assets and the working capital adjustment during the year ended 30 June 2015 which have resulted in an increase to goodwill of \$769,000.

**2014**

Details of the acquisition are as follows:

	<b>Fair value \$'000</b>
Cash and cash equivalents	2,002
Trade receivables	2,915
Plant and equipment, and software	1,577
Brand names	4,538
Trade payables	(1,889)
Deferred tax liability	(553)
Employee benefits	(116)
Other provisions	(1,025)
Deferred revenue	(460)
Other payables	(384)
	<hr/>
Net assets acquired	6,605
Goodwill	27,289
	<hr/>
Acquisition-date fair value of the total consideration transferred	<u><u>33,894</u></u>
Representing:	
Cash paid or payable to vendor	24,364
Working capital adjustment receivable	(638)
Non-controlling interest	10,168
	<hr/>
	<u><u>33,894</u></u>

#### **Note 41. Interests in subsidiaries**

The consolidated financial statements incorporate the assets, liabilities and results of the following wholly-owned subsidiaries in accordance with the accounting policy described in note 1:

<b>Name</b>	<b>Principal place of business / Country of incorporation</b>	<b>Ownership interest</b>	
		<b>2015 %</b>	<b>2014 %</b>
IVF Finance Pty Limited	Australia	100.00%	100.00%
IVFA Sub-Holdings Pty Ltd	Australia	100.00%	100.00%
IVF Australia Pty Ltd	Australia	100.00%	100.00%
Melbourne IVF Holdings Pty Ltd	Australia	100.00%	100.00%
Melbourne I.V.F. Pty. Ltd.	Australia	100.00%	100.00%
The Heptarchy Trust	Australia	100.00%	100.00%
North Shore Specialist Day Hospital Pty Ltd	Australia	100.00%	100.00%
Queensland Fertility Group Pty. Ltd.	Australia	100.00%	100.00%
Spring Hill Specialist Day Hospital Pty Limited	Australia	100.00%	100.00%
The QFG Day Theatres Unit Trust	Australia	100.00%	100.00%
Hunter Fertility Pty Limited	Australia	100.00%	100.00%
Hunter Fertility Unit Trust	Australia	100.00%	100.00%
Bremiera Pty Limited	Australia	100.00%	100.00%
Queensland Fertility Group Gold Coast Pty Ltd	Australia	100.00%	100.00%
Gold Coast Obstetrics & Gynaecology Specialist Services Pty Ltd	Australia	100.00%	100.00%
Mackay Specialist Day Hospital Pty Limited	Australia	100.00%	100.00%
Maroubra Day Surgery Trust	Australia	100.00%	100.00%
City East Specialist Day Hospital Pty Ltd	Australia	100.00%	100.00%
Virtus Health Singapore Pte Ltd	Singapore	100.00%	100.00%
Virtus Health Europe Limited	United Kingdom	100.00%	100.00%
Virtus Health Ireland Limited	Ireland	100.00%	100.00%
Zentra Labs Limited	Ireland	70.00%	70.00%
SIMS Clinic Limited	Ireland	70.00%	70.00%
Xentra Pharm Limited	Ireland	70.00%	70.00%
SIMS Institute Limited	Ireland	70.00%	70.00%
SIMS EDE Limited	Ireland	70.00%	70.00%
IVF Sunshine Coast Limited	Australia	100.00%	-%
Human Assisted Reproduction Ireland (HARI) Limited	Ireland	70.00%	-%
TAS IVF Pty Limited	Australia	70.00%	-%
Virtus Andrology Laboratory Singapore Pte. Ltd	Singapore	90.00%	-%
Virtus Fertility Centre Singapore Pte Limited	Singapore	90.00%	-%
Virtus Health Specialist Diagnostics Pty Limited	Australia	100.00%	-%

The consolidated financial statements incorporate the assets, liabilities and results of the following subsidiaries with non-controlling interests in accordance with the accounting policy described in note 1:

<b>Name</b>	<b>Principal place of business / Country of incorporation</b>	<b>Principal activities</b>	<b>Parent Ownership interest</b>		<b>Non-controlling interest Ownership interest</b>	
			<b>2015 %</b>	<b>2014 %</b>	<b>2015 %</b>	<b>2014 %</b>
SIMS Clinic Limited	Ireland	provision of healthcare services	70.00%	70.00%	30.00%	30.00%
TAS IVF Pty Limited	Australia	provision of healthcare services	70.00%	-%	30.00%	-%
Virtus Fertility Centre Singapore Pte Limited	Singapore	provision of healthcare services	90.00%	-%	10.00%	-%

**Note 41. Interests in subsidiaries (continued)**

*Summarised financial information*

Set out below is the summarised financial information of the non-controlling interests that are material to the consolidated entity. The amounts disclosed are before inter-company eliminations.

	<b>SIMS Clinic Limited</b>	
	<b>2015</b>	<b>2014</b>
	<b>\$'000</b>	<b>\$'000</b>
<i>Summarised statement of financial position</i>		
Current assets	3,998	6,449
Non-current assets	12,443	1,579
Total assets	16,441	8,028
Current liabilities	6,358	5,152
Non-current liabilities	502	27
Total liabilities	6,860	5,179
Net assets	9,581	2,849
<i>Summarised statement of comprehensive income</i>		
Revenue	26,343	1,539
Expenses	(22,941)	(1,265)
Profit before income tax expense	3,402	274
Income tax expense	(514)	(34)
Profit after income tax expense	2,888	240
Other comprehensive income	-	-
Total comprehensive income	2,888	240
<i>Statement of cash flows</i>		
Net cash from operating activities	5,208	631
Net cash used in investing activities	(11,207)	-
Net cash from financing activities	4,923	-
Net increase/(decrease) in cash and cash equivalents	(1,076)	631
<i>Other financial information</i>		
Profit attributable to non-controlling interests	866	72
Dividends payable to non-controlling interests	315	-
Accumulated non-controlling interests at the end of reporting period	12,030	10,240

*Transactions with non-controlling interests*

	<b>Consolidated</b>	
	<b>2015</b>	<b>2014</b>
	<b>\$'000</b>	<b>\$'000</b>
Dividends payable to non-controlling interest	(315)	-
Capital contribution received from non-controlling interest	1,787	-
	1,472	-

#### Note 42. Interests in associates

Interests in associates are accounted for using the equity method of accounting. Information relating to associates that are material to the consolidated entity are set out below:

Name	Principal place of business / Country of incorporation	Ownership interest	
		2015 %	2014 %
Obstetrics & Gynaecological Imaging Australia Pty Ltd	Provision of medical services	50.00%	50.00%
City West Specialist Day Hospital Pty Ltd	Provision of medical services	50.00%	50.00%

#### Summarised financial information

	2015 \$'000	2014 \$'000
<i>Summarised statement of financial position</i>		
Current assets	755	310
Non-current assets	1,456	1,656
Total assets	2,211	1,966
Current liabilities	1,098	1,419
Total liabilities	1,098	1,419
Net assets	1,113	547
<i>Summarised statement of comprehensive income</i>		
Revenue	3,764	2,594
Expenses	(3,201)	(2,405)
Profit before income tax	563	189
Other comprehensive income	-	-
Total comprehensive income	563	189

#### Note 43. Deed of cross guarantee

The following entities are party to a deed of cross guarantee under which each company guarantees the debts of the others:

Virtus Health Limited  
IVF Finance Pty Limited  
IVFA Sub-Holdings Pty Ltd  
IVF Australia Pty Ltd  
Melbourne IVF Holdings Pty Ltd  
Queensland Fertility Group Pty. Ltd.

By entering into the deed, the wholly-owned entities have been relieved from the requirement to prepare financial statements and directors' report under Class Order 98/1418 (as amended) issued by the Australian Securities and Investments Commission ('ASIC').

The above companies represent a 'Closed Group' for the purposes of the Class Order, and as there are no other parties to the deed of cross guarantee that are controlled by Virtus Health Limited, they also represent the 'Extended Closed Group'.

**Note 43. Deed of cross guarantee (continued)**

Set out below is a consolidated statement of comprehensive income and statement of financial position of the 'Closed Group'.

	<b>2015 \$'000</b>	<b>2014 \$'000</b>
<b>Statement of comprehensive income</b>		
Revenue	106,402	103,493
Share of profits of associates accounted for using the equity method	563	189
Trust distributions received	21,184	25,334
Other income	4,794	1,882
Fertility specialists, consumables and associated costs	(28,195)	(28,548)
Employee benefits expense	(34,987)	(32,063)
Depreciation and amortisation expense	(4,906)	(4,594)
Occupancy expense	(6,280)	(6,235)
Advertising and marketing	(2,199)	(1,751)
Practice equipment expenses	(646)	(617)
Professional and consulting fees	(1,505)	(966)
Other expenses	(6,129)	(6,215)
Finance costs	(8,279)	(7,590)
<b>Profit before income tax expense</b>	<b>39,817</b>	<b>42,319</b>
Income tax expense	(11,240)	(12,604)
<b>Profit after income tax expense</b>	<b>28,577</b>	<b>29,715</b>
<b>Other comprehensive income</b>		
Net change in the fair value of cash flow hedges taken to equity, net of tax	(380)	(96)
Other comprehensive income for the year, net of tax	(380)	(96)
<b>Total comprehensive income for the year</b>	<b>28,197</b>	<b>29,619</b>
<b>Equity - retained profits</b>	<b>2015 \$'000</b>	<b>2014 \$'000</b>
Retained profits/(accumulated losses) at the beginning of the financial year	9,058	(11,211)
Profit after income tax expense	28,577	29,715
Dividends paid	(21,300)	(9,446)
Retained profits at the end of the financial year	<b>16,335</b>	<b>9,058</b>

**Note 43. Deed of cross guarantee (continued)**

	2015 \$'000	2014 \$'000
<b>Statement of financial position</b>		
<b>Current assets</b>		
Cash and cash equivalents	9,854	11,902
Trade and other receivables	38,414	39,220
Other	685	762
	<u>48,953</u>	<u>51,884</u>
<b>Non-current assets</b>		
Investments accounted for using the equity method	1,489	1,489
Other financial assets	170,201	149,928
Property, plant and equipment	14,572	14,545
Intangibles	200,567	196,396
Deferred tax	6,418	8,707
Other	76	141
	<u>393,323</u>	<u>371,206</u>
<b>Total assets</b>	<u>442,276</u>	<u>423,090</u>
<b>Current liabilities</b>		
Trade and other payables	14,911	16,072
Income tax	3,060	4,369
Provisions	1,699	1,487
Other	2,977	2,450
	<u>22,647</u>	<u>24,378</u>
<b>Non-current liabilities</b>		
Borrowings	152,120	139,253
Derivative financial instruments	676	137
Provisions	2,489	2,583
Other financial liabilities	7,949	-
	<u>163,234</u>	<u>141,973</u>
<b>Total liabilities</b>	<u>185,881</u>	<u>166,351</u>
<b>Net assets</b>	<u>256,395</u>	<u>256,739</u>
<b>Equity</b>		
Issued capital	238,429	237,135
Reserves	1,631	10,546
Retained profits	16,335	9,058
<b>Total equity</b>	<u>256,395</u>	<u>256,739</u>

**Note 44. Events after the reporting period**

No matter or circumstance has arisen since 30 June 2015 that has significantly affected, or may significantly affect the consolidated entity's operations, the results of those operations, or the consolidated entity's state of affairs in future financial years.

**Note 45. Reconciliation of profit after income tax to net cash from operating activities**

	<b>Consolidated</b>	
	<b>2015</b>	<b>2014</b>
	<b>\$'000</b>	<b>\$'000</b>
Profit after income tax expense for the year	30,441	30,957
Adjustments for:		
Depreciation and amortisation	9,994	8,192
Share of profit - associates	(563)	(189)
Share-based payments	945	456
Amortisation of bank facility fees	911	463
Interest on finance lease facility	13	17
Interest income	(220)	(349)
Doubtful debts expense	775	355
Other non-cash items	(86)	(193)
Net (gain)/loss in disposal of non-current assets	307	170
Interest on other financial liabilities	960	-
Change in operating assets and liabilities:		
Decrease/(increase) in trade and other receivables	(1,388)	1,255
Decrease/(increase) in inventories	(112)	125
Decrease in deferred tax assets	226	2,267
Increase/(decrease) in trade and other payables	(3,589)	2,478
Increase/(decrease) in provision for income tax	(251)	5,591
Increase in other provisions	1,118	929
Increase in other operating liabilities	1,107	17
Net cash from operating activities	<u>40,588</u>	<u>52,541</u>

**Note 46. Earnings per share**

	<b>Consolidated</b>	
	<b>2015</b>	<b>2014</b>
	<b>\$'000</b>	<b>\$'000</b>
Profit after income tax	30,441	30,957
Non-controlling interest	(1,007)	(72)
Profit after income tax attributable to the owners of Virtus Health Limited	29,434	30,885
Add: interest savings on conversion of options	140	157
Profit after income tax attributable to the owners of Virtus Health Limited used in calculating diluted earnings per share	<u>29,574</u>	<u>31,042</u>
	<b>Number</b>	<b>Number</b>
Weighted average number of ordinary shares used in calculating basic earnings per share	79,861,949	79,593,751
Adjustments for calculation of diluted earnings per share:		
Options over ordinary shares	1,067,866	1,087,109
Weighted average number of ordinary shares used in calculating diluted earnings per share	<u>80,929,815</u>	<u>80,680,860</u>
	<b>Cents</b>	<b>Cents</b>
Basic earnings per share	36.86	38.80
Diluted earnings per share	36.54	38.48

## Note 47. Share-based payments

### *Virtus Health Limited Executive Option Plan and Specialist Option Plan ("Virtus Health Limited Share Option Plan")*

The Virtus Health Limited Share Option Plan was adopted by the Board on 11 June 2013. The Virtus Health Limited Share Option Plan was established to reward, retain and motivate fertility specialists and senior executives. Participation in the Virtus Health Limited Share Option Plan is at the Board's discretion and no individual has a contracted right to participate in the Virtus Health Limited Share Option Plan or to receive any guaranteed benefits. Further details are provided in the remuneration report.

Set out below are summaries of options granted under the plans:

#### 2015

Effective grant date	Expiry date	Exercise or base price	Balance at the start of the year	Granted	Exercised/ cancelled	Expired/ forfeited/ other	Balance at the end of the year
11/06/2013	11/06/2018	\$5.68	412,500	-	-	-	412,500
01/07/2013	27/01/2017	\$5.68	438,005	-	(175,000)	-	263,005
01/07/2013	21/01/2024	\$0.00	45,136	-	-	-	45,136
01/07/2013	21/01/2024	\$0.00	96,238	-	-	-	96,238
01/01/2014	01/01/2024	\$8.69	-	29,073	-	-	29,073
03/10/2014	03/10/2024	\$8.57	-	117,251	-	-	117,251
10/11/2014	10/11/2024	\$7.65	-	85,990	-	-	85,990
13/05/2015	13/05/2025	\$7.16	-	7,372	-	-	7,372
13/05/2015	13/05/2025	\$7.53	-	912	-	-	912
13/05/2015	13/05/2025	\$7.94	-	794	-	-	794
13/05/2015	13/05/2025	\$7.96	-	343	-	-	343
13/05/2015	13/05/2025	\$8.01	-	262	-	-	262
			991,879	241,997	(175,000)	-	1,058,876

#### 2014

Grant date	Expiry date	Exercise or base price	Balance at the start of the year	Granted	Exercised	Expired/ forfeited/ other	Balance at the end of the year
11/06/2013	11/06/2018	\$5.68	412,500	-	-	-	412,500
01/07/2013	27/01/2017	\$5.68	-	450,000	(50,000)	-	400,000
01/07/2013	27/01/2017	\$5.68	-	174,082	(136,077)	-	38,005
01/07/2013	21/01/2024	\$0.00	-	45,136	-	-	45,136
01/07/2013	21/01/2024	\$0.00	-	96,238	-	-	96,238
			412,500	765,456	(186,077)	-	991,879

The weighted average exercise price is \$5.50.

The weighted average remaining contractual life of options outstanding at the end of the financial year was 4.8 years (2014: 4 years).



#### Note 47. Share-based payments (continued)

For the options granted during the current financial year, the valuation model inputs used to determine the fair value at the grant date, are as follows:

Grant date	Expiry date	Share price at grant date	Exercise price	Expected volatility	Dividend yield	Risk-free interest rate	Fair value at grant date
01/01/2014*	01/01/2024	\$8.74	\$0.00	25.00%	3.30%	2.70%	\$1.63
03/10/2014	03/10/2024	\$7.78	\$0.00	25.00%	3.30%	2.87%	\$1.20
10/11/2014	10/11/2024	\$7.65	\$0.00	25.00%	3.40%	2.70%	\$1.24
13/05/2015	13/05/2025	\$7.34	\$0.00	20.50%	3.50%	2.15%	\$0.75
13/05/2015	13/05/2025	\$7.34	\$0.00	20.50%	3.50%	2.15%	\$0.19
13/05/2015	13/05/2025	\$7.34	\$0.00	20.50%	3.50%	2.15%	\$0.09
13/05/2015	13/05/2025	\$7.34	\$0.00	20.50%	3.50%	2.15%	\$0.08
13/05/2015	13/05/2025	\$7.34	\$0.00	20.50%	3.50%	2.15%	\$0.06

\* The effective grant date occurred in the prior financial year, however the yearly expense has been reflected in current financial year.

#### *Grants of options - fertility specialists*

Options will be granted on an annual basis to existing fertility specialists who achieve a benchmark level of IVF Cycles above a base or adjusted base number of IVF cycles established in one of the financial years ending after June 2008.

In addition, consistent with the practice pre-listing on the ASX, options will also be granted to new fertility specialists upon commencing a contractual relationship with the company post-listing. The initial benchmark level for new fertility specialists is 50 IVF Cycles and subsequent benchmark levels are at each 50 cycle increment thereafter.

The key terms and conditions to these option grants are set out below:

For existing fertility specialists, options will generally vest equally in three tranches on the third, fourth and fifth anniversary of the grant of the options, conditional upon the fertility specialist performing a number of IVF Cycles in the immediately preceding year not less than 75% of the relevant benchmark in the year pursuant to which the options were awarded.

For new fertility specialists who join the company, options will generally vest equally in three tranches on the third, fourth and fifth anniversary of the grant of the options, subject to:

- the fertility specialist achieving the relevant benchmark (currently 50 IVF Cycles) in a 12 month period during the two years post commencement of the contractual relationship with Virtus and concurrent grant of options; and
- the fertility specialist then achieving a number of IVF Cycles in the year before the relevant vesting date that is not less than 75% of the benchmark number.

In addition, an option may not be exercised unless it is "in the money" (i.e. if the share price at the relevant time is greater than the share price at the time of the option grant).

Fertility specialists will not need to pay an exercise price to exercise the options.

#### *Vesting Conditions*

Options will vest and become exercisable to the extent that the applicable performance, service, or other vesting conditions specified at the time of the grant are satisfied. Vesting conditions may include conditions relating to continuous employment or service, the individual performance of the participant in the Plan or the company's performance.

The Board has the discretion to set the terms and conditions on which it will offer options under the Plan, including the vesting conditions and different terms and conditions which apply to different participants in the Plan.

Upon the satisfaction of the vesting conditions and any other conditions to exercise, each option will be exercisable into a variable number of shares based on the terms of issue of the options. The number of shares to be issued will be calculated by multiplying the applicable component of the offer value of the grant by the amount of the increase in the share price between the share price at vesting compared to the price at grant all divided by the share price at vesting.

#### Note 47. Share-based payments (continued)

Fertility specialists will not need to pay an exercise price to exercise the options.

##### *High Performance Options – Fertility Specialists*

The Board has created a new High Performer Share Incentive Scheme to reward Fertility Specialists who consistently deliver more than 400 cycles per annum for a consecutive three year period

The High Performer incentive will have a performance hurdle whereby Fertility Specialists are required to achieve fresh cycle activity at greater than or equal to 400 cycles per annum over a consecutive three year qualifying period.

The first incentive period commenced on 1 January 2014 and will run for a three year period ending 31st December 2016; The base price at date of grant will be the average daily closing share price for the month ending 31 December 2013; this has been calculated as \$8.69; the base value of the incentive will be \$500,000;

The first vesting date is 1 January 2017 and vesting is also dependent on the ordinary share price at exercise being higher than the base price set at the time of incentive commencement;

- The actual number of vested options awarded will be in accordance with the calculation methodology applied to the Fertility Specialist performance incentive structure;
- Performance option grants may still be accrued for incremental performance above 400 cycles;
- Once a vesting award is achieved after three years of consecutive high performance, a Fertility Specialist may then commence a new three year high performer incentive period. For example in a six year period a Fertility Specialist may achieve 2 vested awards with a base value of \$500,000 each if he/she achieves 400 cycles per annum for a consecutive period of 6 years;
- The 2015-2017 high performer share incentive commenced on 1 January 2015 for all eligible Fertility Specialists who did not achieve 400 cycles in calendar year 2014. The base price at date of grant is the average daily closing share price for the month ending 31 December 2014, which was \$7.42; and
- The high performer share incentive is administered in accordance with the plan rules established in the Virtus Health Limited Specialist Option Plan approved by the Board in June 2013.

In the directors' opinion:

- the attached financial statements and notes comply with the Corporations Act 2001, the Accounting Standards, the Corporations Regulations 2001 and other mandatory professional reporting requirements;
- the attached financial statements and notes comply with International Financial Reporting Standards as issued by the International Accounting Standards Board as described in note 1 to the financial statements;
- the attached financial statements and notes give a true and fair view of the consolidated entity's financial position as at 30 June 2015 and of its performance for the financial year ended on that date;
- there are reasonable grounds to believe that the company will be able to pay its debts as and when they become due and payable; and
- at the date of this declaration, there are reasonable grounds to believe that the members of the Extended Closed Group will be able to meet any obligations or liabilities to which they are, or may become, subject by virtue of the deed of cross guarantee described in note 43 to the financial statements.

The directors have been given the declarations required by section 295A of the Corporations Act 2001.

Signed in accordance with a resolution of directors made pursuant to section 295(5)(a) of the Corporations Act 2001.

On behalf of the directors

A handwritten signature in blue ink, appearing to read "Peter Macourt".

---

Peter Macourt  
Chairman

25 August 2015  
Sydney



## **Independent auditor's report to the members of Virtus Health Limited**

### ***Report on the financial report***

We have audited the accompanying financial report of Virtus Health Limited (the company), which comprises the statement of financial position as at 30 June 2015, the statement of comprehensive income, statement of changes in equity and statement of cash flows for the year ended on that date, a summary of significant accounting policies, other explanatory notes and the directors' declaration for the Virtus Health Group (the consolidated entity). The consolidated entity comprises the company and the entities it controlled at year's end or from time to time during the financial year.

### ***Directors' responsibility for the financial report***

The directors of the company are responsible for the preparation of the financial report that gives a true and fair view in accordance with Australian Accounting Standards and the *Corporations Act 2001* and for such internal control as the directors determine is necessary to enable the preparation of the financial report that is free from material misstatement, whether due to fraud or error. In Note 1, the directors also state, in accordance with Accounting Standard AASB 101 *Presentation of Financial Statements*, that the financial statements comply with International Financial Reporting Standards.

### ***Auditor's responsibility***

Our responsibility is to express an opinion on the financial report based on our audit. We conducted our audit in accordance with Australian Auditing Standards. Those standards require that we comply with relevant ethical requirements relating to audit engagements and plan and perform the audit to obtain reasonable assurance whether the financial report is free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial report. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial report, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the consolidated entity's preparation and fair presentation of the financial report in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the directors, as well as evaluating the overall presentation of the financial report.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

### ***Independence***

In conducting our audit, we have complied with the independence requirements of the *Corporations Act 2001*.

---

**PricewaterhouseCoopers, ABN 52 780 433 757**

Darling Park Tower 2, 201 Sussex Street, GPO BOX 2650, SYDNEY NSW 1171

T: +61 2 8266 0000, F: +61 2 8266 9999, [www.pwc.com.au](http://www.pwc.com.au)

Liability limited by a scheme approved under Professional Standards Legislation.



### *Auditor's opinion*

In our opinion:

- (a) the financial report of Virtus Health Limited is in accordance with the *Corporations Act 2001*, including:
  - (i) giving a true and fair view of the consolidated entity's financial position as at 30 June 2015 and of its performance for the year ended on that date; and
  - (ii) complying with Australian Accounting Standards (including the Australian Accounting Interpretations) and the *Corporations Regulations 2001*.
- (b) the financial report and notes also comply with International Financial Reporting Standards as disclosed in Note 1.

### ***Report on the Remuneration Report***

We have audited the remuneration report included in pages 6 to 19 of the directors' report for the year ended 30 June 2015. The directors of the company are responsible for the preparation and presentation of the remuneration report in accordance with section 300A of the *Corporations Act 2001*. Our responsibility is to express an opinion on the remuneration report, based on our audit conducted in accordance with Australian Auditing Standards.

### *Auditor's opinion*

In our opinion, the remuneration report of Virtus Health Limited for the year ended 30 June 2015 complies with section 300A of the *Corporations Act 2001*.

A handwritten signature in dark ink that reads 'PricewaterhouseCoopers'.

PricewaterhouseCoopers

A handwritten signature in dark ink that reads 'Eddie Wilkie'.

Eddie Wilkie  
Partner

Sydney  
25 August 2015